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Introduction: Genome-wide association studies (GWAS) have allowed the discovery of 
novel and impacting findings concerning the association of single nucleotide polymorphisms 
(SNPs) with the susceptibility and clinical outcome of complex traits, namely in the field of 
oncology.  
Ovarian cancer (OC) is the seventh most incidence cancer in woman worldwide. 
Despite the achieved improvements in diagnosis and treatment, OC is considered the 
deadliest gynecological cancer in the developed world. However, the identification of 
predictive biomarkers for OC first-line treatment remains a challenge and the results from 
candidate-gene studies have not reached the desired clinical implementation. In 
agreement, the research on this field might benefit from the accomplishment of genome-
wide strategies. Since 2009, 15 OC GWAS have been performed, with the discovery of 49 
SNPs associated with disease susceptibility and 46 with impact in the clinical outcome 
(P<5.00x10-2). Despite the achieved results, they present limited implication and further 
validation is mandatory. So far, five validation studies have been conducted which could 
confirm the association of 12 OC susceptibility SNPs, although no clinical outcome 
associated variant was able to be validated.  
Thereby, the purpose of this study was to select and validate the influence of GWAS-
associated variants in an independent cohort of Epithelial Ovarian Cancer (EOC) patients 
from the North region of Portugal.  
 
Methods: Upon the collection of all OC GWAS-identified variants, we submitted all the 
clinical outcome associated polymorphisms to the SNP Prioritization Online Tool (SPOT) 
software, in order to select the most suitable variants to be studied, according to specific 
criteria. Moreover, we conducted a retrospective hospital-based cohort study gathering 339 
EOC patients submitted to first-line treatment. Polymorphisms genotyping was performed 
by TaqMan® Allelic Discrimination methodology, using validated assays. Overall survival 
(OS) and disease-free survival (DFS) were the two clinical endpoints established in this 
study. All statistical tests were two-sided and a 5% level of significance was considered.  
 
Results: Based on the prioritization rankings provided by the SPOT software, we select 
Neuregulin 3 (NRG3) rs1649942 and Brain and reproductive organ-expressed (BRE) 
rs7572644 as two of the most top prioritized clinical outcome associated SNPs. Patients 
carrying the NRG3 rs1649942 A allele presented a significantly longer OS when compared 
to GG genotype patients (log-rank test, P=0.011) in the FIGO IV stage subgroup. No impact 
was observed for early disease stage patients or considering DFS as outcome. We 
hypothesized that NRG3 rs1649942 GG genotype might be associated with the expression 
of peripheral genes that promote the acquisition of an aggressive phenotype, namely with 
a pro-oncogenic role in the metastatic niche. 
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Regarding the BRE rs7572644 polymorphism, we observed that C allele carriers 
exhibit a decreased OS (P=0.014) and DFS (P=0.032), when compared to TT homozygous 
patients, in the subgroup of early stage disease patients (FIGO I/II). Moreover, multivariate 
Cox regression analysis revealed a three-fold increased risk of death (HR, 3.09; 95% CI, 
1.25-7.66; P=0.015) and recurrence (HR, 3.33; 95% CI, 1.35-8.23; P=0.009) for FIGO I/II C 
allele carriers, after adjustment for hormonal status, histology, surgery extension and tumor 
grade. No significant impact was observed for late stage patients. For early disease stage 
patients submitted to first-line treatment, the presence of BRE rs7572644 C allele could 
lead to an improved ability to repair platinum-induced damages and the anti-apoptotic 
activity of EOC cells.  
 
Conclusion: GWAS development will aid to rethink OC genomics much beyond the obvious 
and direct analysis, namely, through the identification of variants lying in regulatory regions 
of the genome with influence on complex genetic networks. Therefore, it is essential to 
analyze GWAS data to address the possible role of associated markers which, ultimately, 
could translate in clinical implementation. The BRE rs7572644 and NRG3 rs1649942 
GWAS-identified variants were validated in an independent cohort of EOC Portuguese 
patients, particularly in specific EOC subgroups considering FIGO staging. Further 
functional post-GWAS analyses are indispensable to understand the biological 
mechanisms underlying the observed results.  
 
 
Keywords: Single nucleotide polymorphisms, GWAS, epithelial ovarian cancer, validation 
study, clinical outcome, Brain and reproductive organ-expressed, Neuregulin 3 
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Introdução: Os genome-wide association studies (GWAS) têm permitido a descoberta de 
novos e importantes resultados no que diz respeito à associação de polimorfismos de 
nucleótido único (SNPs) com a suscetibilidade e desfecho clínico de doenças complexas, 
nomeadamente na área da oncologia.  
 O cancro do ovário (CO) é o sétimo cancro mais incidente na mulher a nível mundial. 
Apesar das melhorias alcançadas no diagnóstico e tratamento, é considerado o cancro 
ginecológico mais letal nos países desenvolvidos. Contudo, a identificação de 
biomarcadores preditivos à primeira linha de tratamento continua a ser um desafio, e os 
resultados obtidos por estudos de genes candidatos não têm alcançado a implementação 
clínica desejada. Desta forma, a investigação nesta área poderá beneficiar da realização 
de estratégias genome-wide. Desde 2009, foram realizados 15 GWAS em CO, levando à 
identificação de 49 SNPs associados com a suscetibilidade para esta doença e 46 com 
impacto no desfecho clinico (P<5.00x10-2). Apesar dos resultados obtidos, eles apresentam 
uma implicação limitada, sendo obrigatória a sua posterior validação. Até à data, cinco 
estudos de validação foram conduzidos, confirmando a associação de 12 SNPs com a 
suscetibilidade para CO, contudo nenhuma variante associada com o desfecho clínico foi 
alvo de validação. 
  Desta forma, o presente estudo tem como objetivo selecionar e validar a influência 
de duas variantes genéticas reportadas por GWAS numa coorte independente de doentes 
com cancro epitelial do ovário (CEO) da região Norte de Portugal. 
 
Métodos: Após a compilação de todas as variantes genéticas reportadas por GWAS 
realizados em CO, submetemos todos os polimorfismos associados com desfecho clínico 
ao software SNP Prioritization Online Tool (SPOT), de modo a selecionar as variantes 
genéticas a ser estudadas, de acordo com critérios específicos. Adicionalmente, 
conduzimos um estudo retrospetivo de base hospitalar do tipo coorte, envolvendo 339 
doentes com CEO submetidas a tratamento de primeira linha. A genotipagem dos 
polimorfismos foi realizada recorrendo à metodologia de discriminação alélica TaqMan®, 
usando assays validados. Os dois desfechos clínicos estabelecidos neste estudo foram a 
sobrevivência global (SG) e a sobrevivência livre de doença (SLD). Todos os testes 
estatísticos foram bilaterais e um nível de significância de 5% foi considerado. 
 
Resultados: Com base nos rankings de priorização fornecidos pelo software SPOT, 
selecionamos duas variantes de elevada priorização associadas com o desfecho clínico de 
doentes com CO, Neuregulin 3 (NRG3) rs1649942 e Brain and reproductive organ-
expressed (BRE) rs7572644. Doentes portadoras do alelo A do polimorfismo NRG3 
rs1649942 apresentaram uma SG significativamente superior quando comparadas com 
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doentes portadoras do genótipo GG (teste log-rank, P=0.011), no subgrupo de doentes em 
estadio FIGO IV. Nenhum impacto foi observado para doentes em estadios precoces da 
doença ou quando considerada a SLD como desfecho clínico. Assim, foi colocada a 
hipótese que o genótipo GG do polimorfismo NRG3 rs1649942 poderá estar associado 
com a expressão de genes periféricos que promovem a aquisição de um fenótipo 
agressivo, nomeadamente com um papel pró-oncogénico no nicho metastático. 
 No que diz respeito ao polimorfismo BRE rs7572644, observamos que portadoras 
do alelo C exibiam uma menor SG (P=0.014) e SLD (P=0.032), quando comparadas com 
doentes homozigóticas para o alelo T, no subgrupo de doentes em estadios iniciais da 
doença (FIGO I/II). Ademais, a análise multivariada de regressão de Cox revelou um risco 
aumentado de morte (HR, 3.09; 95% CI, 1.25-7.66; P=0.015) e recorrência (HR, 3.33; 95% 
CI, 1.35-8.23; P=0.009) em cerca de três vezes, para doentes portadoras do alelo C em 
estadio FIGO I/II, após ajuste para o status hormonal, histologia, extensão da cirurgia e 
grau de diferenciação tumoral. Nenhum impacto significativo foi observado nas doentes em 
estadio avançado da doença. Em doentes em estadios precoces submetidos a tratamento 
de primeira linha, a presença do alelo C do polimorfismo BRE rs7572644 poderá conduzir 
a uma capacidade aumentada de reparação de danos induzidos pela quimioterapia e da 
capacidade anti-apoptótica das células de CEO. 
 
Conclusão: O desenvolvimento de GWAS irá auxiliar no entendimento da genómica do 
CO muito além da análise óbvia e direta, nomeadamente, através da identificação de 
variantes localizadas em regiões regulatórias do genoma com influência em complexas 
interações genéticas. Consequentemente, é essencial analisar os dados obtidos por estes 
estudos de forma a compreender o possível papel dos marcadores associados, o que, em 
última instância, poderá resultar numa possível implementação clínica. As variantes 
previamente identificadas por GWAS BRE rs7572644 e NRG3 rs1649942 foram validadas 
numa coorte independente de doentes portuguesas com CEO, particularmente em 
subgrupos específicos considerando o estadiamento FIGO. Análises funcionais pós-GWAS 
são indispensáveis de modo a perceber os mecanismos biológicos subjacentes aos 
resultados observados.  
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1.1. Genome-wide association studies: a revolutionary tool in genetics research  
 
With the scientific advances achieved in the last decades, it became clear that the 
human genetic variability is considerably higher than the initially expected. Despite some 
genetic variations present low impact in human health, it is considered that a fraction of 
these alterations is able to introduce phenotypic variations that, in a particular context, might 
have an impact in the development of a specific feature or in response to endo/exogenous 
stimulus [1, 2].  
One of the most common genetic alterations are polymorphisms, i.e., DNA 
sequence variations where the minor allele is present at least in one percent of the 
population [3]. The simplest form of this variation corresponds to a single nucleotide 
substitution in DNA sequence, known as single nucleotide polymorphism (SNP) [3, 4]. This 
type of genetic alteration, which is expected to occur every 100-300 base pairs in the 
genome, represents almost 90% of all nucleotide variations. As SNPs are distributed 
throughout the entire genome, their biological effect depends upon their location, ranging 
from silent to gene expression or protein alterations [5]. 
The commonly occurring SNPs contrast with rare genetic variants (mutations), 
usually involved in monogenic disorders, as they introduce detrimental functional changes 
that ultimately lead to the pathological condition. Thus, the common disease/common 
variant hypothesis states that common disorders are possibly prompted by genetic 
variations that are also common in the general population. Consequently, common SNPs 
have low penetrance and the total genetic risk due to common genetic variants might be 
spread across numerous genetic factors [6]. 
Although family-based studies and genetic linkage analysis are successful 
approaches in the discovery of genes (and gene variants) associated with Mendelian traits, 
they present a limited impact in the mapping of common disease associated loci [7]. Thus, 
the development of population-based studies, allied to the advent of sequencing techniques 
and genome research methods, have allowed the discovery of important and impacting 
findings regarding the association of genetic markers with disease susceptibility and clinical 
outcome [8]. Accordingly, since 2005, a new era in genome mapping started with the 
accomplishment of the first genome-wide association study (GWAS) [9]. GWAS allow to 
test, in a cost-effective manner, the association of thousands of SNPs with a particular trait 
simultaneously in thousands of samples, which has revolutionized molecular and genetic 
research [10, 11]. GWAS are considered non-candidate gene studies that use a whole-
genome approach to unravel traits such as anthropometries, pathologies or even response 
to drugs [12-14]. Despite its typical design based on observational studies, other methods 
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including lymphoblastoid cell lines (LCLs) and pooled DNA can be used, as untypical 
strategies.  
It is estimated that nearly 10 million SNPs are inherited in haplotype blocks, meaning 
that a set of them (tagSNPs) are representative of the most SNPs present in each block 
[15]. Thereby, GWAS are based in the principle of linkage disequilibrium (LD), which 
represents the non-random association between alleles at different loci. Generally, loci 
close to each other show a stronger LD than loci distant in the chromosome. Thus, LD 
allows the determination of genetic markers necessary to identify a haplotype, being the 
number of such markers considerably lower than the total number of variants present in the 
population [7]. LD is generally reported in terms of r2, a statistical measure of correlation. 
The higher the r2 value, the greater the information shared by two SNPs, i.e., one allele of 
the first SNP is often carried together with one allele of the second SNP. In practice, it 
implies that there is the need to genotype only one of the two SNPs to detect the complete 
allelic spectrum. Consequently, the LD creates two alternative analyses as the functional 
SNP could be directly associated and correlated with the trait in opposite to the association 
of a tagSNP in high LD with the functional SNP, following an indirect approach [6] (Figure 
1). 
  
 
 
Figure 1 -  Challenges beyond the use of tagSNPs in GWAS. (A): The direct correlation of a variant with a trait could 
occur if the causal variant is found to be associated in the GWAS analysis. On opposite, the causal variant might be in 
high LD with an associated tagSNP, and further analyses are needed to correlate it with a trait of interest. (B): If the 
causal variant is in low LD with the tagSNP, it might not be covered by GWAS analysis. 
 
Figure 1 -  Challenges beyond the use of tagSNPs in GWAS. (A): The direct correlation of a variant with a trait could 
occur if the causal variant is found to be associated in the GWAS analysis. On opposite, the causal variant might be in 
high LD with an associated tagSNP, and further analyses are needed to correlate it with a trait of interest. (B): If the 
causal variant is in low LD with the tagSNP, it might not be covered by GWAS analysis. 
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A consensus presupposes that an r2 ≥ 0.8 is sufficient for tagSNP mapping to reach 
a good coverage of untyped SNPs [16]. By the existence of these two approaches, a GWAS 
significant SNP cannot be assumed as the causal variant and may require further studies 
to map the precise location of the causal variant. Therefore, GWAS virtually allow for the 
putative research of the entire genome [17]. 
Another significant insight from GWAS include the assignment of putative risk 
regions in or adjacent to genes not previously predicted to be involved in the manifestation 
of a trait, associated loci shared by traits not previously related and the association with 
chromosomic regions characterized with low gene content [18]. However, the development 
of GWAS is also associated with some disadvantages, as addressed in Table 1. 
 
Table 1 – Overview of the main advantages and disadvantages of GWAS. 
 
 
Despite the initial enthusiasm about GWAS, the obtained results fell short of 
expectations with the recognition that the identified loci, alone or in aggregation, typically 
explained a limited proportion of trait heritability [20, 21]. This feature, known as “missing 
heritability”, reflects the usually small effect sizes conferred by trait-associated loci (Odds 
Ratio (OR) often < 1.50) [22]. Due to the modest effect sizes conferred by these variations, 
large sample sizes are required to achieve enough statistical relevance [23]. This limitation 
Advantages [16, 19] Disadvantages [10, 11, 16] 
In contrast to candidate gene studies, GWAS 
enable the identification of novel unsuspected 
susceptibility factors which allows a better 
comprehension of a variety of phenotypes. 
 
GWAS are associated with a high rate of false-
positive results 
Typically, GWAS are based in a case-control 
study design, which make them less expensive 
and allow samples acquisition in a relatively 
simple manner when compared to the extensive 
pedigrees used in linkage studies. 
 
Interpretation of obtained results can be 
problematic and require fine mapping of 
associated loci, as well as functional studies to 
understand the biological plausibility of certain 
findings 
GWAS have higher statistical power for detection 
of slight genetic effects than genetic linkage 
studies. 
 
By restricting statistical significance thresholds, 
GWAS need a substantial sample size. 
Since this type of studies is based on LD 
principle, obtained results have a more restrict 
location than genetic linkage studies, leading to a 
rapid identification of pathological variants 
through narrowing regions that will be analyzed in 
subsequent functional studies. 
 
Due to tagSNPs use, GWAS are incapable to 
detect rare susceptibility variants, beyond the 
lack of cost-effectiveness in low LD regions, 
which can represent almost 20% of the genome  
GWAS are cost-effective due to tagSNPs use, 
which cover much of the genetic variation of a 
region of the genome. 
It is necessary a high number of association tests 
(at least one per SNP) 
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is meaningful even for common traits, as cancer. Inclusively, effect sizes conferred by 
variants associated with lung, breast, or prostate cancers, known as the most incident 
cancers, are usually found to be modest, with OR values ranging from one to three [24-26].  
In fact, the search for “missing heritability” has become an important challenge for 
GWAS. Yang and collaborators have proposed three major hypotheses as the source for 
missing heritability: 1) rare variants (frequency < 0.01%) may also have a role in heritability 
estimation, as they can have a great impact on phenotype; 2) common variants with subtle 
effects are not covered by the current available methodologies, prompting an increase in 
sample sizes; 3) heritability estimation found in family studies is frequently overestimated, 
by not avoiding shared environmental effects [27]. Recently, beyond the agreement with 
these three mutually compatible hypotheses, Bourrat and colleagues have proposed that 
the role of nongenetic factors (epigenetics) must also be considered [28]. Since GWAS 
focus exclusively on DNA, this genome-wide approach does not consider non-DNA 
information. Given that some epigenetic factors can be stably inherited (transgenerational 
effect), they could also respond to selection and should be incorporated in the definition of 
heritability [29].  
Another drawback initially proposed for GWAS is that, in contrast to protein-coding 
alterations characteristic of Mendelian diseases, complex traits are mainly influenced by 
noncoding variants with a putative role in genetic regulation [30]. Namely, significant 
variants are broadly enriched in regions that are transcriptionally active (or with a role in 
transcription) in meaningful cell types, although they are absent from transcriptionally idle 
regions in those cell types. However, although some of the largest-effect variants are in 
genes or pathways with a direct role in a trait manifestation (core genes), SNPs that vastly 
contribute for heritability tend to be spread across the genome (peripheral genes). As 
proposed by Boyle and collaborators, for typical traits, an omnigenic model must be 
considered, assuming that regulatory networks are highly correlated, as the expression of 
peripheral genes might have an impact in the regulation or function of core genes. Thereby, 
a phenotype should be related to a dysfunction in associated tissues and a genetic variant 
will only be considered relevant if it has a putative regulatory role (and hence network 
impact) in those tissues. In summary, a phenotype manifestation might not be assigned to 
a single gene or genetic loci, being largely driven by peripheral genes with an indirect role 
in phenotype and propagated through complex regulatory networks for which only a small 
number of core genes have a direct role, which is consistent with most GWAS findings [30] 
(Figure 2). 
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As in GWAS millions of SNPs are tested simultaneously for the association with a 
specific trait, each one with its own false positive probability, the cumulative likelihood to 
detect false positives is high, so multiple testing adjustment is required. A simpler approach 
is to perform a Bonferroni correction by the adjustment of the alpha value, generally set to 
5.00x10-2, which assumes the independence of all performed tests (α = 0.05/k, where k is 
the number of statistical tests conducted) [31]. Thus, a genome-wide significance threshold 
of P<5.0x10-8 has generally been applied in the majority of GWAS. However, given the high 
number of analyses and outcomes addressed in a GWAS, even a P-value ≤ 10-10 might be 
applied to safely confirm an association [23, 32]. Additionally, an adjustment approach 
based in the determination of false discovery rate (FDR) can be used, which estimates the 
false positives among the significant results [33]. Permutation testing is another effective 
strategy widely applied in GWAS, where the response variable is repeatedly shuffled and 
an empirical P-value is registered [34, 35].  
In the last years, GWAS development have demonstrated that common genetic 
variants might indicate underlying susceptibility loci to common diseases. Therefore, GWAS 
have been greatly explored in medical research leading to the identification of positive 
results in several pathologies including type I and II diabetes mellitus [36-43], inflammatory 
bowel disease (10-14) or coronary heart disease (25-27). A field of particular interest for 
Figure 2 – Schematic representation of the omnigenic model. As postulated, several peripheral genes might contribute 
to the regulation of genes (core genes) with a direct role in a trait’s phenotype. Thus, complex genetic networks could 
underlie the manifestation of a particular feature. 
 
Figure 2 – Schematic representation of the omnigenic model. As postulated, several peripheral genes might contribute 
to the regulation of genes (core genes) with a direct role in a trait’s phenotype. Thus, complex genetic networks could 
underlie the manifestation of a particular feature. 
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GWAS development is in oncology, with the identification of genetic markers associated 
with prostate cancer (15-20), breast cancer (21-23), colorectal cancer [44, 45], lung cancer 
[46, 47], gastric cancer [48], pancreatic cancer [49], bladder cancer [50]. A diagram of all 
cancer GWAS-identified variants is represented in Figure 3, according to their chromosomal 
localization.  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Diagram representing the chromosomal localization of all 864 cancer GWAS-identified variants (P<5.00x10-8) [51]. 
 
The prompt increase in GWAS development provided a crucial opportunity to reveal 
the true impact of common genetic variations on complex traits. Besides the drawbacks 
associated with this genomic approach, GWAS findings might have potential clinical 
applicability, as the identification of risk/prognostic markers might lead to the prediction of 
high risk individuals or to the implementation of prophylactic strategies [52, 53]. Additionally, 
it is well known that patients exhibit distinct treatment response profiles, and this variability 
might be influenced by disease pathophysiology and drug metabolism, both features 
thought to be conditioned by individual’s genetic background [54].  
Although candidate gene studies have an important impact for personalized 
medicine, the development of GWAS might contribute with novel and less obvious targets 
to pharmacogenomics [55]. Furthermore, considering the expanded view from polygenic to 
omnigenic complex traits, the identification of peripheral genes (and SNPs) associated with 
drug response or toxicity profiles might be achieved in GWAS, contributing to expand our 
knowledge on variants with putative influence in treatment regulatory network. Actually, 
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these variants might be those that have escaped the negative selective pressures from 
recent and recurrent therapeutic drugs [52]. Thereby, the additional successful identification 
of genes involved in treatment response regulatory networks could be a major achievement 
in the era of treatment individualization [56-63].  
Some GWAS findings are leading to clinical implementation, as the example of 
CYP2C9 and VKORC1 genetic variants (rs9923231 in VKORC1 gene, rs1057910 and 
rs1799853 in CYP2C9 gene), which have been considered by United States (US) Food and 
Drug Administration (FDA) as relevant biomarkers for warfarin dosage establishment [52, 
64].  
 The oncology field is a paradigmatic example of this evident interaction between 
individuals’ genetic profiles and treatment response phenotypes. In fact, the failure of 
response to a particular treatment is often observed in cancer patients and cytotoxic agents 
have a narrow therapeutic index, with potential for toxicity [14]. Thus, research on this field 
might benefit from genome-wide high-throughput approaches, with the identification of new 
genetic markers that could be integrated into predictive clinical nomograms.   
 
 
1.2. Oncobiology and molecular epidemiology  
 
Cancer is the leading cause of death worldwide, overcoming even de number of 
deaths caused by cardiovascular diseases. In 2012, according to the International Agency 
for Research on Cancer (IARC), 14,1 million new cases and 8,2 million deaths occurred 
worldwide due to this pathology [65]. Lung cancer (around 1,2 million new cases/year and 
1,1 million deaths/year) and breast cancer (around 1,7 million new cases/year and 522 
thousand deaths/year) are the most frequently diagnosed and deathly tumor types in man 
and woman, respectively. It is considered that the increase of cancer cases is due, 
especially, to the expansion and ageing of population, as well as the growing prevalence of 
risk factors associated with cancer susceptibility [66]. Thus, it is estimated that in 2030 about 
22,2 million new cases will be diagnosed [67]. 
As a genome disease, originated by the deregulation of biological pathways and 
processes, cancer is characterized by a wide range of dynamic alterations (spontaneous or 
inherited) that affect multiple cellular systems, from molecular activity to cellular 
communication [68]. Namely, carcinogenesis is influenced by individual genetic background 
and is driven by the accumulation of multiple genetic events, as point mutations, 
translocations, and gene copy number variations. Epigenetic processes, as hypo and 
hypermethylation of specific genomic regions or variations in histones modification levels, 
frequently accompany these genetic alterations [68-70]. Despite the constant occurrence of 
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genetic and epigenetic events, only a part of them present selective growth advantage, 
being causal of neoplastic development  [71]. 
Conceptually, tumorigenesis encompass three main stages: initiation, promotion 
and progression [72]. Initiation might occur upon a brief exposure to potent chemical, 
physical or biological carcinogenic agents, by the occurrence of epigenetic alterations and 
by the inheritance of germline alterations, which prompt non-lethal permanent genomic 
damage in normal cells, rendering them susceptible to both neoplastic promotion and 
development. Promotion is a reversible process in which the regular exposure to promoter 
agents prompt the proliferation of initiated cells, which favors the clonal expansion of cells 
with malignant potential. Consequently, the constant promotion of cellular proliferation 
enhances the propagation of damage caused by initiation, as well as increase the risk of 
additional mutations [72-74]. Finally, in the progression stage, additional mutations promote 
the expression of malignant features in propagated cells [73]. 
This complex process ultimately leads to modifications in the physiology of tumor 
cells responsible for the acquisition of particular hallmarks as self-sufficiency in growth 
factors, insensitivity to growth-inhibitory factors, altered cellular metabolism, evasion to 
apoptosis, unlimited replicative potential, sustained angiogenesis, tissue invasion and 
metastasis and capability to escape to immune response [69, 75]. Moreover, the acquisition 
of these hallmarks is also exacerbated by genomic instability and inflammation promoted 
by tumor cells [75]. However, a tumor cannot be seen as an inert mass of cells and the 
interaction with several other types of cells should be considered. Indeed, tumor 
microenvironment plays a relevant role, contributing with external signals to the 
development and manifestation of the malignant phenotype [75, 76]. Therefore, cancer 
development is considered as a dynamic process, where, in a first punctuated phase, 
random genomic alterations could occur, as well as the natural selection of specific clones 
of tumor cells, in subsequent phases [77]. Actually, a paradigmatic example of the dynamics 
in the tumor landscape can be ascertained by the adaptive capacity that cancer cells have 
to almost environmental change, with the unlimited ability to exhibit pathway superposition 
[78-80]. 
 
 
1.3. Ovarian cancer  
 
Ovarian cancer (OC) is the seventh most common cancer among women worldwide, 
although represents the most lethal gynecological cancer in Western countries [66]. In 2012, 
almost 239 thousand newly diagnosed cases and 152 thousand associated deaths (3.6% 
of cases and 4.3% of deaths by cancer in women) were registered [65]. In Portugal, it is 
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estimated that around 620 new OC cases occurred with almost 380 deaths, with an age-
standardized incidence and mortality rates of 8,2 cases and 4,4 deaths/100 000 women, 
respectively [81].  
Based on the World Health Organization (WHO) criteria for gynecological tumors, 
ovarian neoplasms are classified according to its cellular heterogeneity and, therefore, 
might be integrated into three major groups (epithelial, sex cord and ovarian stroma, and 
germ cell tumors) [82]. Although the high cellular diversity, a great proportion (almost 90%) 
of ovarian tumors arise from the epithelial surface [83, 84]. Accordingly, epithelial ovarian 
tumors can be further divided into seven histological subcategories, namely serous, 
mucinous, endometrioid, clear cell, Brenner, seromucinous and undifferentiated (Figure 4). 
[82]. Within these histological subgroups, except for the undifferentiated subtype, epithelial 
tumors can be further characterized grounded on their behavior, being considered as 
benign, borderline or malignant  [85, 86]. In fact, ovarian epithelial malignant tumors 
constitute almost 30% of epithelial neoplasms [85]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Due to the great OC cellular heterogeneity, and considering that each histological 
subtypes exhibit distinct clinical and treatment patterns, the correct staging of the tumor is 
indispensable to a successful disease management. OC staging is surgical, being 
performed based on the International Federation of Gynecologists and Obstetricians (FIGO) 
guidelines [86]. According to these criteria, stage I tumors are confined to ovaries; stage II 
Figure 4 – Ovarian cancer cellular heterogeneity. Ovarian tumors can have an epithelial, sex cord and ovarian stroma, and 
germ cells origin (adapted from [113]). 
 
Figure 4 – Ovarian cancer cellular heterogeneity. Ovarian tumors can have an epithelial, sex cord and ovarian stroma, and 
germ cells origin (adapted from [114]). 
1.Introduction 
 
12 
 
tumors involve one or both ovaries, presenting pelvic invasion, or primary peritoneal tumors; 
stage III tumors involve one or both ovaries, with cytologically or histologically confirmed 
dissemination to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal 
lymph nodes; stage IV tumors encompass those with distant metastasis (excluding 
peritoneal metastasis). Based on the FIGO criteria, OC staging not only provides essential 
information regarding the histopathology of the disease, but also reflects its dissemination 
pattern. In fact, OC dissemination occurs preferentially from primary organ to the peritoneal 
cavity, through exfoliation, transperitoneal migration and malignant cells deployment 
(transcavitary route). Alternatively, ovarian malignant cells might disseminate via lymphatic 
system, through lymph nodes, or hematological system, up to parenchyma of distant 
organs, as liver, lung or brain [87, 88]. However, the transcavitary propagation route is the 
most clinically relevant as it is an early event in the natural history of the disease which, in 
most of cases, has impact in prognosis. Due to this dissemination pattern and its early stage 
indolent nature, several organ systems are already affected at the time of diagnosis [89]. 
In the attempt to characterize the epithelial ovarian carcinogenesis and etiology, 
several theories have been proposed (Table 2). Despite none of these theories completely 
clarify epithelial ovarian cancer (EOC) etiology, it is likely that they act synergistically, 
evidencing the complex and multifactorial nature of ovarian tumors. Nevertheless the 
importance of the proposed theories, age is considered as a major risk factor for OC 
development: 80% of OC cases are diagnosed after the age of 45 years, with a peak of 
incidence after the menopause [90, 91]. 
 
Table 2 – Explicative hypothesis of epithelial ovarian cancer etiology (adapted from [92]) 
Hypothesis Biological mechanism  
Incessant 
Ovulation  
[93-100] 
Ovarian surface epithelium is constantly exposed to repetitive cycles of 
damage (from the ovulation process) and repair (with subsequent cellular 
proliferation), which propitiates the acquisition of genomic lesions in ovarian 
epithelial cells. The accumulation of these lesions might lead to the 
development of inclusion cysts which subsequently can trigger OC. 
Gonadotropins 
[101, 102] 
Excessive stimulation of ovarian epithelial cells by gonadotropins follicle-
stimulating hormone (FSH) and luteinizing hormone (LH) promotes cellular 
proliferation and neoplastic development. 
Hormones  
[98, 100] 
Through the direct interaction with the ovarian epithelium, estrogens and 
androgens might have a tumorigenic role and progestins may confer a 
protective effect against tumorigenesis.   
Inflammation  
[98, 100] 
Inflammatory factors resulting from the ovulatory process or concomitantly 
released with other pathological processes may damage ovarian epithelium 
and trigger tumorigenesis. 
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Moreover, a portion of OC cases (10-15%) arises in individuals with genetic 
predisposition, making it one of the key risk factors in ovarian tumorigenesis [98]. A family 
history of OC confers, in women with affected first-degree relatives, a three/four-fold  
increased risk of OC development [103]. Hereditary Breast and Ovarian Cancer Syndrome, 
which is associated with BRCA1 (3-6%) and BRCA2 (1-3%) gene mutations, is the most 
common cause of inherited OC [104, 105]. Despite the low frequency of these mutations, 
the lifetime risk of OC development for BRCA1 mutation carriers is 40%, whereas for 
BRCA2 mutation carriers is 20%, unlike to the 1,4% lifetime risk for general population [104, 
106]. The second most common cause of inherited ovarian cancer is Lynch Syndrome, 
which is associated with germline mutations in mismatch repair genes MLH1, MSH2, MSH6 
and PMS2 (1-2%) [104, 107]. Though, apart from the already identified syndromes, some 
studies point that the known susceptibility genes explain only a small fraction of the familiar 
risk [8, 108, 109].  
Additionally, endocrine and reproductive factors seem to be important whereby the 
nulliparity, early menarche, late menopause and the exposure to hormone replacement 
therapy are considered as potential risk factors for OC development [84]. 
Due to the asymptomatic nature of the disease and the lack of methods for its early 
detection, nearly 70% of OC cases are diagnosed in an advanced stage. Furthermore, the 
development of resistance to current therapies is a common feature in these patients, which 
results in a 5-year survival rate of only 30% [110, 111]. However, a high 5-year survival rate 
(90%) is seen in patients with localized tumor at diagnosis [111, 112]. 
Over the past decades, significant advances have been achieved in the OC 
treatment. The combination of cytoreductive surgery followed by the doublet of platinum 
(carboplatin or cisplatin) and taxane (paclitaxel or docetaxel), every 21/21 days for 6 cycles, 
has been the standard regimen for EOC first-line treatment  [113, 114]. Although EOC is 
considered a chemosensitive tumor, as most of patients respond to the first-line 
chemotherapy achieving tumor response rates up to 80%, a great percentage of them will 
relapse.  
Disease stage, tumor size, histological subtype, differentiation degree and the extent 
of residual disease are considered as classic prognostic factors for OC. In opposite, the 
determination and selection of predictive biomarkers for OC first-line treatment has proved 
to be a challenge, which establish this field as a domain of high priority research.   
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1.4. Ovarian cancer as a study model for GWAS development 
 
 As previously mentioned, genetic factors are one of the key risk factors for OC [115]. 
Over the years, linkage analyses have concluded that several high penetrance genes have 
a crucial role in the malignant transformation of the ovary, although, with the postulation of 
the “common disease-common variant” hypothesis, common variants have also been 
associated with OC development [116]. Moreover, the identification of variants relevant to 
the response to treatment and survival in OC patients might contribute to a better 
understanding of prognosis, ultimately guiding the selection of improved chemotherapy 
schemes [117]. To date, several candidate gene studies have been performed allowing the 
recognition that individual genetic profiles have the potential to influence inter-patient 
variability in drug response and, hence, OC treatment outcome [92, 118-129]. Some of the 
obvious candidate genes encode drug metabolism enzymes or DNA repair mediators that 
can influence treatment response, toxicity profiles and, lastly, survival endpoints [130, 131]. 
Genome-wide strategies that encompass SNP genotypes, drug-induced cytotoxicity in cell 
lines and gene expression data are potential models for the identification of predictors of 
treatment and clinical outcome in OC patients [132].  
To this date, 15 OC GWAS have been performed, most of them evaluating 
susceptibility loci (Supplementary Table 1), although the impact regarding clinical outcome 
has also been investigated (Supplementary Table 2) [133-145]. To highlight that the majority 
of the variants reviewed and presented are associated with a significant P-value 
(P<5.00x10-2), despite only a small fraction reached the desired genome-wide threshold 
(P<5.00x10-8). 
Replicated and/or validated susceptibility and clinical outcome associated SNPs 
lying within genes are schematically grouped in Figure 5 according to the molecular 
pathway(s) they are involved. Each group was constituted based on information available 
in an online database, Reactome, which resulted in the establishment of seven main groups 
[146]. 
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1.4.1. OC susceptibility GWAS 
 
 In 2009, the first OC GWAS was conducted by Song and collaborators concerning 
the identification of common OC susceptibility alleles [133]. The authors have evaluated 
more than 500 thousand SNPs, reporting the association of 12 SNPs at 9p22 locus with the 
risk of OC development (P < 10-8). The most significant associated SNP (rs3814113) was 
also genotyped in a replication set which confirmed the association (combined OR=0.82; 
Ptrend=5.10x10-19). Moreover, the authors reported that the association is distinct regarding 
the histological subtype, being the strongest association obtained for serous OC subgroup 
(OR = 0.77; Ptrend=4.10x10-21). This SNP is localized near the BNC2 gene, which encodes 
a zinc finger protein highly expressed in reproductive tissues and involved in DNA 
transcription (Supplementary Table 3). However, none of the top SNPs seem to be 
Figure 5 - Molecular pathways in which replicated and/or validated susceptibility and clinical outcome associated SNPs are 
involved, according to the information presented in Supplementary Tables 4 and 5. Highlighted in red are SNPs associated 
with OC susceptibility; highlighted in green are SNPs associated with OC clinical outcome and highlighted in dark are SNPs 
associated both with OC susceptibility and clinical outcome. Briefly, “signal transduction” set refers to SNPs in genes involved 
in signaling transduction pathways; “cell membrane molecules” set includes cell surface receptors and transporters subgroups; 
“cellular processes” set covers SNPs lying in genes involved in cell cycle, apoptosis, cellular senescence, cell motility and 
vesicle-mediated transport and catabolism; “genetic information processing” set encompass SNPs involved in gene 
expression and replication processes, as well as ubiquitin-mediated proteolysis processes; “metabolism” set enclose genetic 
variants associated with biomolecules and energy metabolism; in “DNA damage response” set, SNPs affecting DNA damage 
repair systems are presented and “others” set includes subgroups related to less representative pathways. 
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associated with BNC2 expression or to be near predictable or known transcription regulation 
elements, demanding for further evaluations [133]. 
After the publication of the first GWAS, ten additional OC susceptibility studies have 
been conducted  [134, 135, 137-141, 143, 147, 148] (Supplementary Table 1). Most of these 
studies were case-control based, although studies conducted by Lu et al. [137] and Earp et 
al. [141] used a pooled DNA-technique in one of the GWAS phases. This approach allows 
to reduce the cost of genotyping, maintaining the study power, through the construction of 
two sets of pools composed by a combination of the same amount of DNA from cases and 
controls. Subsequently, these pools are genotyped and allelic frequencies calculated [149]. 
Briefly, 49 SNPs were found to be associated with susceptibility to EOC. Among them, 14 
SNPs reached genome-wide significance for EOC risk, being the three most significant the 
genetic variants rs3814113 (Ptrend=5.10x10-19), rs2072590 (P=4.50x10-14) and rs199661266 
(P=1.00x10-9) [133, 135, 143] (Supplementary Table 1). The SNP rs3814113 lies ~44kb 
upstream of BNC2 gene, which encodes a protein highly expressed in reproductive tissues, 
being a potential regulatory protein of DNA transcription [133]. The genetic variant 
rs2072590 lies within a non-coding region downstream of HOXD3 and upstream of HOXD1 
and it tags SNPs in the HOXD3 3’ untranslated region, genes found to be implicated in 
cancer development [135]. The associated variant rs199661266 locates in intron 6 of 
ATAD5, a gene involved in DNA damage response  [143] (Supplementary Table 3).  
In this set of GWAS, were also found several markers associated with the 
susceptibility to particular EOC subtypes, highlighting the role of distinct molecular 
pathways underlying each histological subtype [134, 135, 138-141, 143, 147, 148]. In this 
context, 31 SNPs were found to have an influence in the susceptibility to OC serous subtype 
(top associated SNP: rs3814113; Ptrend=4.10x10-21) [133], 13 SNPs were associated with 
endometrioid subtype (top associated SNP: rs555025179; P=4.50x10-8) [148], 13 SNPs 
with mucinous subtype (top associated SNP: rs112071820; P=1.50x10−13) [148], seven 
SNPs with clear cell subtype (top associated SNP: rs757210; P=3.90x10-6) [139] and one 
SNP with low-malignant potential serous subtype (top associated SNP: rs9609538; 
P=7,00x10-4) [141]. Five additional SNPs were associated with less representative subtypes 
(top associated SNP: rs1413299; P=9.69x10-6) [140] (Supplementary Table 1).  
Regarding effect sizes conferred by associated markers, they have been found to 
have generally low to moderate effects, with ORs ranging from 0.67 to 2.19 (Supplementary 
Table 1). These values are in accordance with genetic variants associated with the 
susceptibility for other cancer types, as previously mentioned [24-26]. 
Concerning OC susceptibility GWAS, a highlight must be given to the study 
performed by Bolton and colleagues that reported that the BRCA1-interacting gene 
MERIT40 might be a relevant gene underlying the genetic influence to EOC, supporting a 
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role of the 19p13 locus in OC susceptibility. These results revealed special interest by the 
fact that genetic variants in this region have already been identified as modifiers of breast 
cancer risk in BRCA1-mutated carrying patients [134]. 
 
1.4.2. OC clinical outcome GWAS 
 
 As OC patients may inherently vary in their ability to respond to treatment, genetic 
association studies have sought to identify variants with impact in clinical outcome. In 2010, 
Bolton and colleagues performed the first OC clinical outcome GWAS, evaluating more than 
250 thousand SNPs, from which rs8170 (Hazard Ratio (HR)=1.11; Ptrend=5.20x10-4) and 
rs2363956 (HR=1.09; Ptrend=5.60x10-4), located in locus 19p13, were associated with OC 
survival (Supplementary Table 2). The presence of the variant allele was associated with a 
slightly decrease in patients’ survival for both variants [134]. However, this first GWAS did 
not replicate any survival-associated SNPs.  
In the total, five OC GWAS have evaluated the association of genetic markers with 
patients’ clinical outcome [134, 136, 142, 144, 145] (Supplementary Table 2). Despite the 
case-control study design used by Bolton and collaborators, the other four clinical outcome 
GWAS were cohorts or used a LCLs approach. Briefly, in most cell line-based GWAS, LCLs 
are exposed to increasing concentrations of a drug, and individual cellular sensitivity to the 
agent is measured by cell growth inhibition or apoptosis ability [14]. The GWAS is 
simultaneously conducted, often including genome-wide genotype and gene expression 
evaluation [150]. In the context of a cell-based model, Huang and colleagues employed a 
GWAS to identify germline variants with clinical applicability. In this study, the risk allele of 
rs1649942 was significantly associated with an increased risk of disease progression and 
death in phase 1 patients submitted to carboplatin-based chemotherapy, with a greater 
genetic contribution among the subset of patients with optimally debulked tumors. Since 
clinical outcomes obtained from optimally debulked patients might represent the ideal 
treatment scenario for OC, in order to eliminate the confounder effect associated to the 
presence of residual disease, the role of rs16499942 was addressed in this subset of 
patients. However, the results were not replicated in phase two, which was attributable to a 
different categorization of residual disease and to the fact that patients were presumed, but 
not known, to have had standard doses of paclitaxel and carboplatin, which might reflect 
the impact of distinct clinical definitions across studies [136].  
Clinical outcome in OC patients has been reported to be under the influence of 46 
SNPs. The three most associated SNPs reported by these GWAS were rs185229225 
(Pmeta=2,2x10-7), rs3842595 (Pmeta=2,6x10-7) and rs4910232 (P=4,7x10-7), although any of 
the 46 associated SNPs have reached genome-wide significance [142, 145]. The 
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polymorphism rs185229225 lies within BOD1L1, a gene coding a protein found to be a 
protection factor of replication fork [145, 151] (Supplementary Table 4). SNP rs3842595 is 
located within SNCAIP gene, which is involved in ubiquitin mediated proteolysis system and 
in Parkinson’s’ disease [145] (Supplementary Table 4). With respect to variant rs4910232, 
it lies within a non-coding region [142] (Supplementary Table 4). Nevertheless, four SNPs 
were associated with clinical outcome in serous subtype, being rs7874043 the most 
significant SNP (P=7,3x10-5), located within a putative regulatory element of TTC39B gene 
and, consequently, potentially involved in the regulation of High Density Lipoprotein-C 
(HDL-C) levels [144] (Figure 5, Supplementary Table 4). Moreover, rs8170 was associated 
with endometrioid subtype (Ptrend=3.00x10-2), and lies within MERIT40, a gene involved in 
DNA double strand break response pathway and with a role in cell cycle checkpoints [134] 
(Figure 5, Supplementary Table 4). 
In concordance with the variants identified in susceptibility OC GWAS, SNPs that 
were found to be associated with OC patients’ clinical outcome do not confer large effect 
sizes, despite the slightly increase in HR values (ranging from 1.07 to 1.91) (Table 3).  
Regarding OC clinical outcome GWAS, a special focus must be given to the study 
performed by Johnatty and colleagues, which selected SNPs for replication in the presence 
of a good imputation quality (r2 ≥ 0.9) to minimize the risk of false positives. This study was 
one of the largest performed studies that evaluated the presence of genetic variation across 
the genome for a possible association with OC clinical outcome, either in regard to first-line 
standard treatment and regardless of treatment scheme. Once again, by the role of residual 
disease extension as predictive marker, patients were only included if they received a 
minimum of cytoreductive surgery and had available information on level of residual 
disease. Factors of appreciation of this study are that, beyond the SNPs prioritization on 
basis of good imputation quality, the final estimates were derived from meta-analysis of all 
available imputed data and genotypes from OC consortiums and the analysis was restricted 
to European invasive EOC patients with standardized clinical and pathological information 
[142].      
Moreover, French and collaborators have identified two SNPs, located in a intronic 
region of TTC39B. Functional tests have showed that the likely functional SNP is 
rs7874043, which alters transcription factor (TF) binding and, ultimately, chromatin 
conformation (Figure 5, Supplementary Table 4). Moreover, the silencing of PSIP1, one of 
the targets of the regulatory element, significantly impaired DNA damage repair by 
homologous recombination in OC cell lines, suggesting that PSIP1 is a potential target for 
a therapeutic approach as previously suggested for other tumors [152]. A high expression 
of PSIP1 is also associated with high risk of recurrence proposing that altered PSIP1 
expression may be a functional consequence of associated SNP [153]. The strengths of the 
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study performed by French and colleagues are that they only included cases that received 
standard first-line treatment (duplet carboplatin/paclitaxel) and the progression-free survival 
(PFS) was the survival endpoint evaluation, rather than overall survival (OS) following 
exposure to multiple drugs [144]. 
 
 
1.5. OC and GWAS: the challenge of post-GWAS research    
 
 Since Song and collaborators conducted in 2009 the first OC GWAS, several loci 
have been identified as being associated with susceptibility and clinical outcome, although 
without reaching definitive and conclusive results. In fact, as previously mentioned, despite 
the relative success of GWAS, they are associated with some disadvantages, when 
compared to other genetic studies, as the GWAS’ low statistical power in addition to high 
rates of false positive results. Consequently, a great number of association tests are 
necessary, as it is a wide study size due to strict statistical significance thresholds [10, 11, 
16].  
Additionally, the failure to conclude an association in OC GWAS might be caused 
by a variety of factors such disease heterogeneity as in most GWAS the initial analysis, that 
allows SNP selection for succeeding phases, combine all EOC histological subtypes 
whereas the subsequent phases might be performed based on a subgroup stratification. An 
example is the study performed by Bolton and colleagues [134]. Limitations in GWAS might 
also reflect heterogeneous clinical criteria and the use of self-reported ethnicity. However, 
the later limitation could be overcome using ancestry informative markers (AIMs) to define 
ethnicity, as exemplified in studies conducted by Song, Bolton and Goode [133-136].   
Another factor that might explain the spurious results obtained by GWAS concerning 
to cancer treatment response is that, for most cancers, a wide variety of chemotherapeutic 
regimens is administered, which might contribute to heterogeneity in treatment response 
[154-156]. Moreover, the ability to obtain follow-up data for a suitable number of patients 
might restrict the detection of statistical relevance regarding survival endpoints. Accordingly, 
pharmacogenomics GWAS have failed to identify associations with relevant effect sizes for 
a genome-wide significance mainly due to the small samples sizes, as the low incidence of 
OC preclude the acquisition of a large quantity of samples, as well as cancer drug non-
responders are often less frequent than responders. Moreover, drug response is not always 
measured in a completely quantitative manner, which prompt a heterogeneous phenotype 
definition [144]. Therefore, in order to overcome the small number of samples available, 
most of the performed OC GWAS have recruited patients from several consortiums [133-
135, 139, 142-144]. 
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Thereby, the major challenge in in this area of research is to discriminate the true 
associations from false positives through attempts to replicate positive findings in 
subsequent studies. Thus, it becomes essential to adopt strategies that enable researchers 
to support the obtained results. In this perspective, fine mapping, functional analyses or the 
study of populations from many geographical ancestries have become important 
approaches that will complement GWAS findings and will help to achieve a better 
comprehension of the role of the identified variants in disease genetics [10, 20, 157, 158].  
Validation studies in an independent set or using different methodologies are 
another strategy with possible impact in GWAS evaluation. They allow the assessment and 
confirmation of previously reported results in order to validate them and/or to refute chance 
or possible bias as probable cause of association [159]. Moreover, they minimize false 
positive results observed in common low penetrance alleles, since only a limited number of 
variants are truly risk alleles [160-162]. Another reason why validation is important is that, 
in a first GWAS, the effect of an association is usually overestimated. Thereby, as validation 
studies are made, the estimate effect declines, in a phenome known as “winner’s curse” 
[31]. Consequently, the calculation of validation sample size is a major determinant to be 
taken in consideration [163]. 
Although the terms “replication” and “validation” are interchangeably used, they have 
different meanings: in a replication study, the replication sample is an independent dataset 
drawn from the original sample (discovery sample), in an attempt to confirm the effect in the 
GWAS target population [164] (Figure 6). As loci are replicated as truly causal, extension 
into multiple ethnicities is highly recommended to determine the generalizability and 
consistency of the proposed markers [165, 166]. On the other hand, in validation studies, 
the validation sample and the original sample are originated from different populations, 
meaning that an independent validation subset is used [165].  
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The intention of replication and validation studies is not only to provide further 
evidence to accept or refute the original association but also to systematic evaluate the 
potential sources of error or bias underlying the GWAS [166]. Validation studies have been 
made for several types of cancers, however, to the best of our knowledge, only five studies 
were conducted in OC [136, 137, 140, 141, 167]. As mentioned before, Huang and 
collaborators used a cell-based approach to identify SNPs associated with carboplatin 
sensitivity and performed, subsequently, a two-phase validation in clinical samples for SNPs 
found to be associated in the cell-based phase. However, no subsequent confirmation was 
performed for the second stage validation [136]. In the studies conducted by Lu et al (2012) 
and Earp et al (2014), a pooled DNA strategy was used and, to validate associated SNPs 
from the previous phase, they were genotyped in a large set of OC samples. Although in 
the later, all SNPs associated with OC susceptibility were validated, Lu and colleagues were 
not able to confirm any association [137, 141]. In a study conducted in Han Chinese women, 
Chen and collaborators tested the association of previously reported SNPs with OC risk 
and validated one SNP (rs9303542). In 2014, an independent validation study conducted 
by Mostowska and collaborators evaluated the association of seven GWAS-associated 
Figure 6 – Schematic representation of the rational beyond validation and replication studies. In a GWAS, hundreds of 
thousands of SNPs are genotyped in a limited number of samples in a discovery phase, in order to select variants 
associated with the interest trait. Then, these SNPs are genotyped in replication stages with larger sample sizes to confirm 
their association. Validation studies use a sample set recruited from a different population to confirm reported associations. 
 
Figure 6 – Schematic representation of the rational beyond validation and replication studies. In a GWAS, hundreds of 
thousands of SNPs are genotyped in a limited number of samples in a discovery phase, in order to select variants 
associated with the interest t ait. Then, these SNPs are genotyped in replication stages with larg r sample sizes to confirm 
their association. Validation studies use a sample set recruited from a different population to confirm reported associations. 
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SNPs in a Polish population regarding susceptibility to OC. They have statistically validated 
loci 9p22 and 8q24 for all OC patients and, more specifically, for serous subtype [167].  
 As previously mentioned, OC candidate gene studies are mainly conducted for 
variants in genes or pathways with an obvious role in the disease or in the response to 
platinum/taxane duplet. Besides their putative direct influence, no conclusive results have 
been achieved, since only a few solid associations were reported and, even less, were 
positively replicated and/or validated [116, 168]. The existence of non-definitive 
associations seems to be concordant with the OC GWAS results, as only a small part of 
associated GWAS variants are consistently replicated and/or validated and few robust 
associations have been reached (P<5.00x10-8) (Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 23 
 
 
 
 
 
 
 
 
 
 
 
 
2. Aims 
 
  
 24 
 
 
2. Aims 
25 
 
2.1. Main aim 
 
Independent validation of GWAS-identified Neuregulin 3 (NRG3) rs1649942 and 
Brain and reproductive organ-expressed (BRE) rs7572644 genetic variants as predictive 
biomarkers, in a cohort of OC patients from the North region of Portugal. 
 
 
2.2. Specific aims 
 
▪ Literature review on OC GWAS; 
 
▪ Selection of genetic variants previously reported to be associated with clinical outcome 
in OC patients; 
 
▪ Validation of GWAS-associated NRG3 rs1649942 and BRE rs7572644 in an 
independent cohort of OC patients. 
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3.1. Study population description 
 
We performed a retrospective hospital-based cohort study on European female 
patients with the histological confirmation of EOC, admitted between January of 1996 and 
December of 2012 in the departments of gynecology and oncology of the Portuguese 
Institute of Oncology, Porto, Portugal (IPO-Porto). From this group of patients were 
excluded those who were only admitted for a second opinion or to be submitted to specific 
treatment techniques, namely hyperthermic intraperitoneal chemotherapy or with follow-up 
in other institutions. A cohort of 339 conveniently sampled patients from the North region of 
Portugal and for which biological material was available was enrolled.  
Tumor staging was performed according to the FIGO guidelines and the assessment 
of the tumor response to chemotherapy was based on Rustin criteria [169, 170]. Patients’ 
clinicopathologic and follow-up data were obtained from their medical records. The mean 
age of included patients was 55 years (median = 54 years; minimum = 18 years; maximum 
= 80 years), from which 57.2% were post-menopausal women. The majority of patients was 
diagnosed with advanced disease stage (57.5% FIGO III/IV). The distribution considering 
the extent of residual disease occurred as follows: in 41.9% of the cases was achieved an 
optimal surgical resection whereas 11.8% and 26.2% presented residual disease ≤2 cm 
and >2 cm, respectively (no information available for 20.1% of the patients). Considering 
the histological subtype, 56.9% presented serous tumors, 12.1% clear cell, 10.0% 
mucinous, 10.0% endometrioid and the remaining 10.9% less common subtypes. 
Regarding the therapeutic strategy, 89.5% of patients were submitted to the standard 
regimen based on cytoreductive surgery followed by a combination of Paclitaxel 
(175mg/m2) and Cisplatin (75 mg/m2) or Carboplatin (Area under the curve 5-7.5), although 
doses were adjusted whenever severe toxicity was reported. Chemotherapy alone (5.1%), 
neoadjuvant chemotherapy (3.7%) or only surgery (1.7%) were also considered as first-line 
treatment options.  
Follow-up information was reviewed from the initial diagnosis through December 
2016 in 322 patients (95% of all patients). The mean follow-up of all participants enrolled in 
the study was 89.9 months (median = 68.5 months; minimum = 2 months; maximum = 246 
months).  
A written informed consent was obtained from each participant prior to their inclusion 
in this study, according to Helsinki Declaration principles. Furthermore, this study was 
approved by the ethics committee at IPO-Porto (CES IPO:286/2014). 
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3.2. Laboratory procedures 
 
3.2.1. Sample collection and genomic DNA extraction 
 
Peripheral venous blood samples were obtained with a standard technique and 
collected in ethylenediamine-tretaacetic acid (EDTA)-containing tubes.  
Genomic DNA was extracted from peripheral blood samples using the extraction kit 
Qiagen®, QIAmp DNA Blood Mini Kit (Qiagen® 51106), as indicated by the manufacturer’s 
procedure. 
 
3.2.2. SNP selection  
 
To select the variants to be validated in this study, we gathered all polymorphisms 
statistically associated with OC clinical outcome, identified in a recently accepted review on 
OC GWAS studies carried-out by our group [171], which were further submitted to the SNP 
Prioritization Online Tool (SPOT) software [172]. Based on the priority ranking returned by 
the SPOT software (which takes into account the P-value reported by the original study and 
the possible functional impact of each variant considering its genomic location), the minor 
allele frequency (MAF) in the Iberian population (>15%), the availability of the respective 
genotyping assay, the putative relevance in ovarian biological pathways and the previously 
accomplishment of validation studies, the NRG3 rs1649942 and BRE rs7572644 SNPs 
were selected, among the top prioritized polymorphisms . 
 
3.2.3. Polymorphisms genotyping 
 
 Genotyping for NRG3 rs1649942 and BRE rs7572644 genetic variants was 
performed using TaqMan® Allelic Discrimination methodology (Figure 7), through the Real-
Time Polymerase Chain Reaction (PCR) technique. The two validated assays were: 
C__29412070_10, targeting the rs7572644 polymorphism, whose VIC dye probe was 
associated with C allele and FAM dye probe was associated with T allele 
(TAAGAGCCATGGGGAACCATAGCTG[C/T]AGGGAAACCGTGATGCCTGCCAGCA) 
and C___8914657_10, targeting rs1649942 polymorphism, whose VIC dye probe was 
associated with A allele and FAM dye probe was associated with G allele 
(GCCCTGCGGTTGAGGGTTCTTGCCA[A/G]TTCGATTCTAATACATGAACACTTT). 
 Real-time PCR reactions were carried out using 6 µL reaction mixture, containing 
the following components: 2.5 µL of TaqPathTM ProAmpTM Master Mix (1x), 0.125 µL of 
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TaqMan® SNP Genotyping Assay mix, 2.375 µL of sterile water and 1 µL of genomic DNA. 
Thermal conditions were based in the activation of Taq DNA Polimerase at 95°C for 10 
minutes, followed by 45 cycles at 92°C for 15 seconds to denature DNA chain and 60°C for 
1 minute to primers pairing and extension. 
 Amplification was detected and data analyzed through the StepOne Plus Real-Time 
PCR system and StepOne Software (version 2.3 Applied Biosystems). In order to ensure 
the quality of genotyping, two negative controls were included in each amplification reaction 
(to avoid false positives) and double sampling was performed in, at least, 10% of the 
samples, with an accuracy above 99%.  The genotype results were independently evaluated 
by two researchers, who were blinded to patient clinical status. 
 
 
 
 
3.3. In silico analysis 
 
 In silico analysis was conducted to due to the lack of knowledge regarding the 
functional consequence of both intronic variants studied. Therefore, the Human Splicing 
Finder 3.0 was used to understand the possible influence of both SNPs in the respective 
Figure 7 – Exemplification of an allelic discrimination plot for NRG3 rs1649942 polymorphism. 
 
Figure 7 – Exemplification of an allelic discrimination plot for NRG3 rs1649942 polymorphism. 
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gene pre-mRNA splicing. Furthermore, to identify putative regulatory elements recognition 
binding sites created by the different alleles, the MotifMap online tool was also used. 
 
 
3.4. Statistical analysis 
 
 Statistical analysis was performed resorting to the computer software IBM® SPSS® 
Statistics for WindowsTM (version 24.0, SPSS Inc, 2016). 
Associations between genetic polymorphisms and patients’ clinicopathologic 
characteristics were assessed using chi-square test (χ2), for categorical variables, whereas 
student’s t-test was used for continuous variables (age).  
Kaplan-Meier method was used to obtain survival curves and the log-rank test was 
used to compare the probabilities of survival. The most suitable genetic model for each 
variant was established after an initial comparison between Kaplan-Meier curves under the 
log-additive genetic model. Subgroup stratification was also performed according to FIGO 
stage (FIGO I/II vs FIGO III vs FIGO IV).  
OS, defined as the interval of time between diagnosis and patients’ death by EOC 
(EOC specific survival) or the last clinical evaluation, and disease-free survival (DFS), 
defined as the period from the date of diagnosis until the date of first recurrence or last 
clinical evaluation in patients with complete response to the first-line treatment, were the 
two clinical endpoints evaluated in this study. Endpoint definition was based on RECIST 
criteria [173].  
The death and recurrence risk were estimated by a Cox proportional HR, along with 
95% confidence interval (CI), adjusted for hormonal status (pre- vs post-menopausal), 
histologic subtype (serous vs others), surgery (complete vs others) and tumor grade (grade 
1 vs grade 2 vs grade 3 vs grade 4). Cause of death was determined from the patients’ 
medical records.  
 All tests were two-sided and a 5% level of significance was stablished. 
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4.1. Descriptive statistics of NRG3 rs1649942 and BRE rs7572644 polymorphisms 
 
 NRG3 rs1649942 genotype distribution (MAF, 28.3%) was 51.7% for homozygous 
AA (n=169), 40.0% (n=131) for heterozygous AG and 8.3% for homozygous GG (n=27) (4% 
of genotyping failure). Regarding the variant BRE rs7572644 (MAF, 21.1%), 63.2% of the 
patients were found to be homozygous for the T allele (n=208), 31.3% were heterozygous 
TC (n=103) and 5.5% homozygous for the C allele (n=18) (3% of genotyping failure).  
Our data did not reveal significant statistical differences between the different 
genotypes of NRG3 rs1649942 and BRE rs7572644 and patients clinicopathological 
characteristics, namely age (P=0.481 and P=0.968, respectively), FIGO stage (P=0.554 
and P=0.402, respectively), histological subtype (P=0.060 and P=0.338, respectively), 
hormonal status (P=0.571 and P=0.271, respectively) and extent of residual disease 
(P=0.867 and P=0.863, respectively). 
For the cohort involved in this study, the mean OS and DFS were 89.39 and 79.83 
months, respectively. 
 
 
4.2. Association of NRG3 rs1649942 polymorphism with the clinical outcome of OC 
patients 
  
Concerning the survival curves obtained using Kaplan-Meier method and log-rank 
test, no statistically significant differences were observed for the survival time of all patients 
according to NRG3 rs1649942 genotypes (P=0.708), neither when considering a subgroup 
analysis restricted to early disease stage (FIGO I/II; P=0.644) or FIGO III patients 
(P=0.986). However, a significant impact of NRG3 rs1649942 genotypes was observed for 
the FIGO IV stage patients (P=0.027). Considering a recessive genetic model (AA/AG 
genotypes vs GG genotype), no significant differences on survival were observed 
(P=0.699). Regarding the subgroup with distant metastasis at diagnosis, a consistent 
association was observed, as A allele carriers had a higher survival when compared to GG 
genotype carriers (P=0.011) (Figure 8). Namely, a mean OS time of 61.96 months was 
observed for patients with A allele that contrast with the 13.00 months reported for GG 
genotype patients. Anew, the protective effect of NRG3 rs1649942 reference allele was not 
observed in early stages (FIGO I/II; P=0.377) or FIGO III stage patients (P=0.869). 
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Regarding the impact of NRG3 rs1649942 polymorphism with DFS for the entire 
cohort, no statistically significant associations were observed, considering either the log-
additive and the recessive genetic model (P=0.356 and P=0.158, respectively). Additionally, 
no significant association was observed when the analysis was stratified by FIGO staging, 
independently of genetic model applied (data not showed). Furthermore, multivariate 
analyses for the risk of death and recurrence of EOC patients were calculated, adjusted for 
EOC prognostic variables (hormonal status, histological subtype, surgical extension and 
tumor grade). However, this analysis did not reveal a predictive impact of NRG3 rs1649942 
regarding the risk of death and recurrence of EOC patients (HR, 1.30; 95% CI, 0.63-2.67; 
P=0.477 and HR, 0.59; 95% CI, 0.24-1.45; P=0.251, respectively). 
 
 
4.3. Association of BRE rs7572644 polymorphism with the clinical outcome of OC 
patients 
 
  Concerning the impact of BRE rs7572644 polymorphism on survival, no significant 
associations were observed either under a log-additive (TT vs TC vs CC; P=0.181) or 
Figure 8 – Overall survival by Kaplan-Meier and log-rank test for the subgroup of EOC patients with FIGO IV stage disease 
at diagnosis, according to NRG3 rs1649942 polymorphism genotypes (recessive genetic model). The group of patients 
with A allele carrier genotypes (AA/AG genotypes) had significantly higher survival when compared with patients with GG 
genotype (P=0.011).   
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dominant genetic model analysis (CC/TC genotypes vs TT genotype; P=0.889). None the 
less, upon a stratified analysis, a statistically significant impact on survival time and BRE 
rs7572644 genotypes was observed in FIGO I/II and FIGO III stage patients (P=0.038 and 
P=0.040, respectively).  No statistically significant difference was noticed for the later stage 
OC patients (P=0.139). Furthermore, under the dominant genetic model (CC/TC vs TT), we 
observed that TT homozygous genotype patients had an extended long-term survival of 
39.53 months when compared to C allele carriers (214.46 vs 174.93 months; P=0.014), in 
the subgroup with early stage disease at diagnosis (FIGO I/II) (Figure 9). In opposite, for 
patients with FIGO III and IV stage, TT homozygous patients showed a shorter survival than 
those with CC/TC genotypes, even though these associations did not reach the significance 
level (mean survival time (months) for FIGO III stage patients: TT genotype = 100.52, C 
allele = 135.02; P=0.052; and FIGO IV stage patients: TT genotype = 44.99, C allele = 
70.06; P=0.384, respectively). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No statistically significant associations were observed considering the DFS as 
outcome, independently of the genetic model assumed (data not showed). However, for 
early stage patients, we observed that C allele carriers had a lower DFS time than TT 
genotype patients, with CC and TC genotype carriers presenting recurrence at 175.13 
Figure 9 – Overall survival by Kaplan-Meier and log-rank test for the subgroup of EOC patients with FIGO I/II stage disease 
at diagnosis, according to BRE rs7572644 polymorphism genotypes (dominant genetic model). The group of patients with TT 
genotype had significantly higher survival when compared to C allele carrier genotype patients (P=0.014).   
 
Figure 9 – Overall survival by Kaplan-Meier and log-rank test for the subgroup of EOC patients with FIGO I/II stage disease 
at diagnosis, according to BRE rs7572644 polymorphism genotypes (dominant genetic model). The group of patients with TT 
genotype had significantly higher survival when compared to C allele carrier genotype patients (P=0.014).   
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months and TT homozygous patients at 214.23 months (P=0.032) (Figure 10). No further 
statistical associations were observed for FIGO III (P=0.224) and FIGO IV stage patients 
(P=0.897).  
 
 
 
 
 
 
 
 
 
 
 
 
Furthermore, a multivariate analysis was performed to estimate the risk of death and 
recurrence of FIGO stages I/II patients, considering the BRE rs7572644 polymorphism and 
known EOC prognostic factors (hormonal status, histological subtype, surgical extension 
and tumor grade) (Table 3). We observed that C allele carriers had not only a threefold 
increased risk of disease recurrence but also death compared to TT homozygous genotype 
patients (HR, 3.33; 95% CI, 1.35-8.23; P=0.009 and HR, 3.09; 95% CI, 1.25-7.66; P=0.015, 
respectively) (Table 3).  
 
 
 
 
Figure 10 – Disease-free survival by Kaplan-Meier and log-rank test for the subgroup of EOC patients with FIGO I/II stage 
disease at diagnosis, according to BRE rs7572644 polymorphism genotypes (dominant genetic model). The group of 
patients with TT genotype had significantly higher survival when compared to C allele carrier genotype patients (P=0.032). 
 
Figure 10 – Disease-free survival by Kaplan-Meier and log-rank test for the subgroup of EOC patients with FIGO I/II stage 
disease at diagnosis, according to BRE rs7572644 polymorphism genotypes (dominant genetic model). The group of 
patients with TT genotype had significantly higher urvival when compared to C allele carrier genotype patients (P=0.032). 
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Bold values are statistically significant. 
 
 
 
 
 
 
 
 
 
 
 Risk of death Risk of recurrence 
Variable HR 95% CI P-value HR 95% CI P-value 
BRE rs7572644 
(TT genotype vs C allele) 
3.09 1.25-7.66 0.015 3.33 1.35-8.23 0.009 
Hormonal status 
(Pre- vs Post-menopause) 
1.17 0.98-1.39 0.086 1.25 1.06-1.47 0.007 
Histology 
(serous vs others) 
0.63 0.26-1.56 0.319 0.45 0.18-1.10 0.078 
Surgery 
(complete vs other) 
1.90 0.61-5.97 0.271 3.37 1.21-9.36 0.020 
Tumor grade  
(Grade 1 vs 2 vs 3 vs 4) 
1.05 0.91-1.21 0.489 1.00 0.86-1.15 0.946 
Table 3 –  Multivariate Cox regression analysis on the risk of recurrence and death in early stage patients (FIGO I/II) at 
diagnosis, considering several clinical and pathological variables. 
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Besides OC low incidence, this gynecological cancer is a main factor of morbidity 
and mortality [118]. Namely, the high OC-associated lethality can be explained by the lack 
of specific and sensitive screening methods and by the anatomic location of this organ which 
allows the painless development of the tumor, both factors that preclude the early diagnosis 
of the disease [110, 111]. Although the implementation of platinum-based chemotherapy 
schemes has increased the response rates to first-line treatment up to 70%, the 
development of chemotherapy resistance by most patients remains a major hurdle,  which 
also contributes for  the slight percentage of individuals who survive 5 years after the initial 
diagnosis (around 30%) [120]. Thus, it becomes essential to identify biomarkers that 
contribute to the optimal selection of therapeutic schemes, namely by dose adjustment 
according to each individual’s risk of relapse (risk stratification) [118].  
The application of genome-wide strategies was faced with the potential to 
revolutionize the molecular oncology field. However, namely regarding OC, numerous 
results have been obtained by GWAS, although without reaching definitive conclusions. 
Therefore, it becomes essential to meticulously analyze these data to conclude the possible 
role of associated markers which, ultimately, could translate in clinical implementation [52]. 
To the best of our knowledge, five validation studies have been conducted in the attempt to 
validate OC GWAS associated markers, four of them evaluating susceptibility associated 
markers and the study conducted by Huang and colleagues being the only which attempted 
to validate clinical outcome associated variants [136, 137, 140, 141, 167]. Thus, it is evident 
the need to validate clinical outcome associated markers, not only because of the lack of 
this type of studies, but also due to the potential clinical applicability arising from truly causal 
variants. Furthermore, only the study conducted by Mostowska et al. was independently 
performed [167]. Thus, the present study was the first designed with the purpose to 
independently validate OC clinical outcome GWAS findings in a Caucasian population.   
 
 
5.1. Association of NRG3 rs1649942 polymorphism with the clinical outcome of OC 
patients 
 
 The genetic variant rs1649942 corresponds to an intronic variation that leads to the 
replacement of an adenine (A) by a guanine (G) in the NRG3 gene [174]. This gene codifies 
a homonymous extracellular protein, being a member of the neuregulin family, which has 
been shown to have low expression levels in normal ovarian tissues [175]. This protein has 
the capacity to bind exclusively to ErbB4 and, so, to be involved in ErbB signaling, which, 
in turn, seems to be related to ovarian tumorigenesis [136, 175-179] (Figure 11).  
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Figure 11 – Specificity of ligands to Epidermal Growth Factor Receptor (EGFR) family. Epidermal Growth Factor (EGF), 
Transforming Growth Factor-α (TGF-α), Amphiregulin (AR) and Epigen (EPG) are specific ligands for EGFR; Betacellulin 
(BTC), Heparin-binding EGF (HB-EGF) and Epiregulin (EPI) bind both EGFR and ErbB4; Neuregulin 1/2 (NRG1/2) have the 
capacity to bind ErbB3/4; Neuregulin 3/4 (NRG3/4) are exclusive ligands for ErbB4. No ligand is known to bind ErbB2, although 
it has the strongest kinase activity. Thus, it is the preferential heterodimerization partner of other ErbB receptors. In contrast, 
ErB3 lacks its kinase activity, so it needs to heterodimerize with other partners to have signaling potential (adapted from [180]). 
 
 
This SNP was firstly identified to be associated with response to cytotoxic drugs in 
a study conducted by Huang et al. (2007) that aimed to discover genetic variants that 
contribute to cisplatin-induced cytotoxicity, concluding that rs1649942 was significantly 
associated with cisplatin IC50 [132]. Despite NRG3 rs1649942 was first reported a decade 
ago it still is not well characterized [132]. Interestingly, although the most part of intronic 
variants lies within consensus regions of exon-intron junctions and directly affect splicing, 
some of them might lie in regions with a regulatory role in the maturation of pre-mRNA [181, 
182]. Additionally, polymorphisms lying within regulatory regions of the genome may lead 
not only to alterations in TFs binding motifs, but also influence methylation patterns and the 
alternative splicing of target genes and, hence, affecting their transcription [183-185]. The 
in silico analyses’ results provided by the Human Splicing Finder 3.0 and MotifMap 
bioinformatic tools revealed that the rs1649942 genetic variant is unlikely to be in a splicing 
or in a TF binding site. Nevertheless, this variant has already been shown to be associated 
with the expression levels of target genes, which suggest that its functional consequence 
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might be due to a regulatory network role [132, 136]. Effectively, some regions of the 
genome harbor genetic alterations capable of regulate the expression of near (cis-
regulation) or distant genes (trans-regulation), being defined as expression quantitative trait 
loci (eQTL) [183]. Namely, it has been shown that these regulatory properties appear to 
clarify the role of a large proportion of non-coding variants [186].  
Although the GWAS data was not validated in the overall analysis, our results 
indicate that NRG3 rs1649942 polymorphism was significantly associated with OS in the 
subgroup of FIGO IV stage patients, either considering a log-additive (P=0.027) and a 
recessive genetic model analysis (P=0.011). Therefore, in the subgroup of individuals with 
advanced disease at diagnosis, a lower survival time was observed for patients carrying the 
GG genotype (13.00 months), in contrast to A allele carriers who presented a better OS 
(61.96 months). However, no impact on the time until tumor recurrence was noticed.  
Huang et al. [136] reported, for the first time, the association of NRG3 rs1649942 
variant with the clinical outcome of OC patients, submitted to the first-line treatment. An 
association between this variant and PFS was observed for all the patients (P=0.008), being 
even more marked in the subgroup of optimal debulked patients (P=0.002), as GG genotype 
carriers presented a lower survival time when compared with AA/AG genotype patients. 
Thus, the negative impact assigned to GG genotype is consistently observed in our study. 
Furthermore, considering OS analysis, Huang and colleagues also reported a reduced 
survival time for GG homozygous patients compared with AA/AG genotype patients 
(P=0.014), although this association was only observed in the subset of optimally debulked 
patients. Moreover, the regulatory role of NRG3 rs1649942 was demonstrated, namely by 
being associated with the expression levels of several genes, some of them associated with 
carboplatin IC50  [132, 136, 187]. One of these regulated genes, KYNU, known to be 
involved in tryptophan metabolism, was already reported to impact the OS of advanced 
stage serous OC patients submitted to the standard treatment and its overexpression was 
associated with an increase in the cellular sensitivity to carboplatin [136, 188, 189]. Taking 
together, these results suggest a regulatory role as the main functional consequence of this 
SNP.  
In advanced disease stages, the metastatic process assumes a great 
preponderance being responsible for the high mortality rates [190]. Namely, the 
dissemination to the peritoneal cavity is an early phenomenon in the natural history of the 
ovarian disease since the malignant cells follow the peritoneal fluid, obeying to the intra-
abdominal pressure variations, being able to avoid anoikis and, hence, having the ability to 
survive in suspension. The molecular mechanisms implied in OC cell dissemination are not 
fully described, though several biological pathways might be involved, with distinct gene 
expression profiles between tumor stages [110, 191-193]. Considering the previous 
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assumptions, we hypothesized that NRG3 rs1649942 GG genotype might lead to the 
expression of peripheral genes that promote the acquisition of an aggressive phenotype, 
namely with a pro-oncogenic role in the metastatic niche. Consequently, GG genotype 
patients with distant metastatic disease at diagnosis have a lower survival time compared 
with A allele carriers. However, for less spread disease stages, the expression of core genes 
involved in the metastatic process might have a more direct and preponderant role when 
compared to the complex regulatory network in which the NRG3 gene might be involved. In 
fact, neuregulins have already been associated with metastatic process, namely in 
medulloblastoma, breast and papillary thyroid tumors [194, 195]. Regarding OC, it was 
reported the relevant contribution of the interaction Neuregulin 1 (NRG1)-ErbB3 in omentun 
metastasis via a hematogenous route [196]. Consequently, the quantification of NRG3 
circulatory levels might be considered in future studies. Despite the association with OS, 
the impact of this variant in the DFS time appears to be irrelevant, which might indicate a 
preponderant role of further clinical and pathological factors in the time until EOC 
recurrence. 
 
 
5.2 Association of BRE rs7572644 polymorphism with the clinical outcome of OC 
patients 
 
The polymorphism rs7572644 lies within a intronic region of the BRE gene and leads 
to the substitution in the DNA chain of a thymine (T) by a cytosine (C) [145, 174]. BRE, also 
known as BABAM2 (BRISC and BRCA1 A complex member 2), codifies a protein involved 
in DNA damage response [145] (Figure 12). Namely, it is involved in the maintenance of 
the integrity of the BRCA1-A complex in the nucleus, although BRE could also act as an 
anti-apoptotic protein [145, 197, 198]. In the ovary, BRE deficiency was found to promote 
follicular atresia, through the enhancement of granulosa cells’ apoptosis [199]. Regarding 
OC, some evidences point a possible role of BRE in disease susceptibility and 
chemotherapy response [145, 200]. As the functional impact of rs7572644 is not fully 
described yet, in silico analyses revealed a possible null impact in splicing mechanisms as 
well as no predicted TF binding site. However, the minor allele of this variant was shown to 
be associated with chemotherapy sensitivity [145].  
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Figure 12 – Schematic representation of BRCA1-A complex. This DNA repair complex is structurally constituted by a dimer 
of heterotetramers composed by MERIT40, Abraxas, BRCC36 and BRE (adapted from [201]). 
 
 
None significant results were observed in the overall cohort, according to the BRE 
rs7572644 genotypes. Upon subgroup analysis, we observed that TT genotype patients 
had a prolonged OS when compared to C allele carriers (dominant genetic model), for the 
subgroup of patients with early stage disease (FIGO I/II) at diagnosis (P=0.014). Moreover, 
despite the non-significant result for FIGO stage III subgroup (P=0.052), there is a trend for 
the impact of this variant in the survival of these subset of individuals. Moreover, in the 
subgroup of FIGO stages I/II patients, TT genotype was associated with improved DFS 
(P=0.032), meaning that C allele carrier patients would take less time until the emergence 
of recurrent disease. Additionally, using multivariate Cox regression models, and 
exclusively evaluating patients with localized tumor at diagnosis, we verified that C allele 
carriers have a three-fold increase in the risk of death and recurrence, adjusted for known 
OC prognostic factors. Namely, this polymorphism is the only variable significantly 
associated with the risk of death of this subset of patients. Thus, BRE rs7572644 
polymorphism could be a useful predictive marker for early stage disease patients.  
Considering the role of BRE in DNA damage repair, the presence of BRE rs7572644 
C allele could lead to the translation of a more stable isoform with higher affinity for the 
BRCA1-A complex. Consequently, there might be an increase in the complex integrity which 
can promote an improved DNA damage repair response. Although early stage disease 
patients have tumor confined to ovaries (FIGO stage I) or with pelvic extension/primary 
peritoneal cancer (FIGO stage II), patients are submitted to platinum-based chemotherapy, 
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after cytoreductive surgery, meaning that cancer cells that have not been completely 
eradicated by surgery are exposed to the action of DNA damage agents. Considering the 
presence of BRE rs7572644 C allele, and hence an improved DNA repair damage 
response, residual cancer cells could promptly repair the platinum-induced damages, which 
could result in a precocious and higher risk of disease relapse. Moreover, BRE was also 
found to be an anti-apoptotic protein [198]. Namely, BRE was considered to be involved in 
lung cancer cisplatin resistance through its anti-apoptotic activity mediated by the protein 
kinase B signaling pathway [202]. Thereby, beyond the possible impact in DNA repair, we 
further hypothesized that BRE rs7572644 C allele is associated with an increased anti-
apoptotic activity of EOC cells, promoting a decrease in the cellular sensitivity to 
chemotherapy. Supporting this assumption is the fact that PI3K/Akt signaling pathway (in 
which protein kinase B has a major effector role) activation has already been associated 
with cisplatin resistance in OC [202]. In agreement to what was hypothesized for NRG3 
rs1649942 polymorphism, BRE rs7572644 could also exert its effect through the regulation 
of target genes. Despite in silico analyses have not predicted the binding of any TF at this 
locus, this putative eQTL SNP could act through several other mechanisms, as mentioned 
before [183-185]. Therefore, the present variant could be potentially associated with the 
expression of peripheral genes with an additional negative role in the prognosis of OC 
patients. Moreover, this SNP could not be the functional variant itself, as it is in linkage 
disequilibrium (r2>0.8) with other four intronic variants (rs7581813, rs2337700, rs55796876 
and rs11691385) which could be causal of the disease. 
On the other hand, the influence of BRE rs7572644 does not appear to be relevant 
in FIGO III and IV stage patients, although a trend was seen for FIGO III stage patients. 
Besides the undoubtedly importance of DNA repair mechanisms in OC susceptibility and 
treatment response, namely for the newly targeted therapies, its role in the metastatic 
process might not be so determinant, being that function fulfilled through additional and 
more relevant molecular networks [110]. In this sense, as disease dissemination increases 
less relevant might be the role of BRE in the maintenance of genomic integrity. Accordingly, 
BRE was reported to promote tumor cell growth but not metastasis of mouse Lewis lung 
carcinoma cells transfected with this protein in syngeneic mice models [203].  
Variant BRE rs7572644 was firstly reported by Fridley et al., which used a cell-based 
model to associate drug response phenotypes with genetic variants [145]. The influence of 
each identified variant with any clinical endpoint was not assessed in the original study, 
although it was observed that BRE rs7572644 C allele carriers were sensitive to the 
carboplatin and paclitaxel combination. Therefore, intuitively, patients who are sensitive to 
chemotherapy might have an improved outcome. However, the data obtained in the present 
study appear to be in disagreement with the chemosensitive properties conferred by C allele 
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in the study of Fridley et al. [145]. Nevertheless, the results obtained in LCLs GWAS should 
be taken carefully as one of the limitations inherent to this approach is that it does not 
consider interactions between several biological pathways in response to chemotherapy, 
which can be a possible bias as it not fully represents the complexity of drug effect [14, 136, 
145].  
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GWAS development will aid to rethink OC genomics much beyond the obvious and 
direct analysis. Namely, multiple small effect genetic variants, most of them lying in 
regulatory regions of the genome and potentially irrelevant to a particular disease, might 
indirectly exert its influence on trait phenotypes through the regulation of complex networks, 
affecting thereby the expression and activity of a restrict core set of genes [30]. This theory 
seems to be consistent with the results obtained for OC GWAS, as most of the associated 
variants are in regulatory sequences of genes with an unapparent direct role in this 
gynecological neoplasia. The combination of genomic knowledge might be the key to 
unravel OC genetics and further work is needed to underpin this assumption. 
In this perspective, the present study aimed to validate two intronic variants 
associated with the clinical outcome of OC patients previously reported by GWAS. In fact, 
this is the first study which attempts to confirm the association of GWAS-identified variants 
with the clinical outcome of EOC patients, in an independent cohort, namely, in a 
Portuguese population. In sum, we were able to independently validate both NRG3 
rs1649942 and BRE rs7572644 variants in our population, as they seemed to have a role 
in the clinical outcome.   
In our population, the two genetic polymorphisms previously highlighted in GWAS 
presented a FIGO staging-specific behavior. Although promising, these results, particularly 
regarding NRG3 rs1649942 variant, should be taken carefully due to the under-power in 
FIGO stage IV A allele carriers. Though underpowered in the stratified analysis, this study 
represents one of the largest series of OC patients published so far. Furthermore, clinical-
pathological characteristics of included patients are similar to the entire series admitted in 
our institution, meaning that we can accept the representativeness of our cohort. Moreover, 
a low number of individuals was lost to follow-up (attrition bias of 5%), although the extended 
period of follow-up time. Furthermore, the low range of 95% CIs determined in the 
multivariate analysis could demonstrate the low variance in the concluded outcomes. 
We suggest that further validation studies should be conducted in larger cohorts in 
order to reinforce the study power. Additionally, the need for additional post-GWAS 
analyses is evident, in order to perceive the genetic context in which each variant is inserted 
and to understand their biological plausibility regarding OC. To achieve this purpose, future 
analysis should be oriented to fine map the regions where these variants lie, as well as for 
the accomplishment of functional studies. Further studies evaluating the regulatory network 
of each associated region should be conducted resorting to the analysis of chromatin 
markers which tag promoters or enhancers/silencers [144]. Additionally, eQTL studies might 
be informative of the influence of these polymorphisms in the expression levels of several 
genes and would contribute to the linking between identified variants and their target genes 
[158]. 
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 The success of GWAS suggests that this genomic approach will continue to be 
applied for the assessment of variants with probable impact in complex traits. However, 
their development should be complemented with post-GWAS analyses, in order to identify 
and confirm the most significant associated variants and to understand their potential 
biological involvement [10, 20, 157, 158]. Ultimately, GWAS findings might be of potential 
interest for clinical practice, in the era of personalized medicine, since some variants 
identified through these studies might be important independent prognostic markers or 
assume a predictive role of therapy response and, consequently, help in the adoption of 
treatment options suited to individual genetic profile. 
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Appendix 1 
Supplementary Table 1 - Overview of OC susceptibility GWAS 
Study Associated SNPs Population 
No. 
cases/controls 
(combined) 
MAF Locus Gene 
Overall risk Subtype-specific risk 
OR (95% CI) P-value OR (95% CI) P-value 
Histological 
subtype 
Song et al. 
2009 rs3814113 
ǂ, #
 European ancestry 8761/11831 0.32 9p22.2 
~44 kb 
upstream of 
BNC2 gene 
0.82 (0.79-0.86) a 5.10x10-19 c 
0.77 (0.73-0.81) a 4.10x10-21 c Serous 
0.86 (0.79-0.94) a 1.00x10-3 c Endometrioid 
0.83 (0.76-0.91) a 6.60x10-5 c Other 
Bolton et al. 
2010 
rs8170 ǂ European ancestry 10496/13172 0.11 e 
19p13 
MERIT40 1.12 (1.07-1.17) a 3.60x10-6 c 1.18 (1.12-1.25) a 2.70x10-9 c Serous 
rs2363956 
ǂ
 European ancestry 10480/13176 0.46 
e ANKLE1 1.10 (1.06-1.15) a 1.20x10-7 c 1.16 (1.11-1.21) a 3.80x10-11 c Serous 
Goode et al. 
2010 
rs2072590 
ǂ
 
European ancestry 
10406/16340 0.18 e 2q31 
Non-coding 
region 
1.16 (1.12-1.21) a 4.50x10-14 
1.20 (1.14-1.25) a 3.80x10-14 Serous 
European ancestry 1.30 (1.17-1.44) a 7.30x10-7 Mucinous 
European ancestry 1.13 (1.04-1.22) a 2.40x10-3 Endometrioid 
rs2665390 
ǂ
 
European ancestry 
10406/17369 0.07 e 3q25 TIPARP 1.19 (1.11-1.27) a 3.20x10-7 
1.24 (1.15-1.34) a 7.10x10-8 Serous 
European ancestry 1.23 (1.08-1.40) a 1.90x10-3 Endometrioid 
rs10088218 
ǂ
 
European ancestry 
10462/16362 0.09 e 
8q24 
Gene desert 
region 
0.84 (0.80-0.89) a 3.20x10-9 
0.76 (0.70-0.81) a 8.00x10-15 Serous 
European ancestry 1.21 (1.05-1.40) a 1.00x10-2 Clear cell 
rs1516982 
ǂ
 European ancestry 10472/54111 0.16 
c 0.86 (0.82-0.91) a 2.00x10-8 0.81 (0.76-0.86) a 3.30x10-11 Serous 
rs10098821 
ǂ, # European ancestry 10414/16136 0.10 c 0.83 (0.78-0.89) a 4.70x10
-9 0.75 (0.70-0.81) a 2.30x10-13 Serous 
rs9303542 
ǂ, #
 European ancestry 10242/13091 0.32 
e 17q21 SKAP1 1.11 (1.06-1.16) a 1.40x10-6 1.14 (1.09-1.20) a 1.40x10-7 Serous 
Lu et al. 
2012 
No significant associations 
White, non-
Hispanic 
342/643 
- - - - - - - - 
(White, non-
Hispanic) 
6195 (5620)/7854 
(6966) 
Couch et al. 
2013 
BRCA1 
mutation 
carriers 
rs17631303 
ǂ
 European ancestry 2273/11997 0.22 
17q21 
PLEKHM1f 1.27 (1.17-1.38) a, g 1.40x10-8 c    
rs183211 
ǂ
 European ancestry 2281/12070 0.26 NSF f 1.25 (1.16-1.35) a, g 3.10x10-8 c    
rs4691139 ǂ European ancestry 2280/12070 0.52 4q32.3 Chr4:164987569 1.20 (1.17-1.38) a, g 3.40x10-8 c    
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Supplementary Table 1 - Overview of OC susceptibility GWAS (cont.) 
 
Study Associated SNPs Population 
No. 
cases/controls 
(combined) 
MAF Locus Gene 
Overall risk Subtype-specific risk 
OR (95% CI) P-value OR (95% CI) P-value 
Histological 
subtype 
Pharoah et 
al. 2013 
rs11782652
 ǂ
 European ancestry 
16283/23491 
0.07 8q21 CHMP4C 1.19 (1.12-1.26) a 5.50x10-9 1.24 (1.16-1.33) a 7.00x10-10 Serous 
rs1243180 
ǂ
 European ancestry 0.31 10p12 MLLT10 1.10 (1.06-1.13) a 1.80x10
-8 
1.11 (1.07-1.15) a 1.40x10-7 Serous 
1.08 (1.00-1.15) a 3.80x10-2 Endometrioid 
rs757210 
ǂ
 European ancestry 0.37 17q12 HNF1B 1.05 (1.02-1.09) 
a 9.00x10-4 
1.12 (1.08-1.17) a 8.10x10-10 Serous 
0.80 (0.72-0.88) a 3.90x10-6 Clear cell 
0.89 (0.81-0.99) a 2.70x10-2 Mucinous 
Earp et al. 
2014 
rs11108890 
#
 European ancestry 
78/392 
0.04 
Chr12: 
96137530 
LOC105369927 f   1.38 (1.16–1.66) b 4.00x10-4 
Mucinous 
1483/21530 
rs933518 
#
 European ancestry 
78/392 
0.08 
Chr16: 
53079622 
   1.26 (1.11–1.45) b 8.00x10-4 
1483/21530 
rs17106154 
#
 European ancestry 
78/392 
0.07 
Chr14: 
68230927 
Lies within a 
~150kb LD region 
of ZFP36L1 
  1.21 (1.06–1.39) b 5.80x10-3 
1483/21530 
rs970651 
#
 European ancestry 
78/392 
0.16 
Chr13: 
47351705 
   1.16 (1.05–1.28) b 4.20x10-3 
1483/21530 
rs7981902 
#
 European ancestry 
78/392 
0.13 
Chr13: 
47368792 
   1.15 (1.03–1.28) b 1.14x10-2 
1483/21530 
rs2190503 
#
 European ancestry 
114/392 
0.13 
Chr7: 
50710111 
Identify a locus 
upstream/intronic 
to GRB10 gene 
  1.12 (1.04–1.22) b 5.00x10-3 
Endometrioid/
clear cell 
2903/21528 
rs6593140 
#
 European ancestry 
114/392 
0.12 
Chr7: 
50765627 
  1.09 (1.03–1.17) b 6.00x10-3 
2903/21528 
rs2329554 
#
 European ancestry 
114/392 
0.22 
Chr7: 
50842524 
  1.12 (1.03–1.22) b 6.00x10-3 
2903/21528 
rs9609538 
#
 European ancestry 
68/392 
0.24 
Chr22: 
31139832 
~5 bp downstream 
BPIL2 and ~500 
bp upstream 
C22orf28 
  0.84 (0.76–0.93) b 7.00x10-4 LMP Serous 
892/21529 
Chen et al. 
2014 
rs1413299 
ǂ
 Han Chinese 
2496/3975 
0.42 9q22.33 COL15A1 1.24 (1.15-1.33) b 1.88x10-8 d 
1.25 (1.14–1.38) b 2.13x10-6 d Serous 
1.30 (1.15–1.45) b 9.69x10-6 d Other 
rs1192691 
ǂ
 Han Chinese 0.41 10p11.21 
245 kb upstream 
of exon 1 of 
ANKRD30A 
0.81 (0.75-0.87) b 2.62x10-8 d 
0.80 (0.72–0.87) b 1.13x10-6 d Serous 
0.83 (0.73–0.92) b 1.16x10-3 d Other 
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Supplementary Table 1 - Overview of OC susceptibility GWAS (cont.) 
  
Study Associated SNPs Population 
No. 
cases/controls 
(combined) 
MAF Locus Gene 
Overall risk Subtype-specific risk 
OR (95% CI) P-value OR (95% CI) P-value 
Histological 
subtype 
Chen et al. 2014 
(cont.) 
rs11175194 
ǂ
 Han Chinese 
2496/3975 
0.37 12q14.2 SRGAP1 0.82 (0.76-0.88) b 1.14x10-7 d 
0.83 (0.75–0.91) b 6.22x10-5 d Serous 
0.73 (0.59–0.90) b 3.36x10-3 d Endometrioid 
0.86 (0.76–0.97) b 1.40x10-2 d Other 
rs633862 
ǂ
 Han Chinese 0.42 9q34.2 
5 kb 
upstream of 
ABO gene 
0.83 (0.77-0.89) b 8.57x10-7 d 
0.86 (0.79–0.95) b 1.95x10-3 d Serous 
0.73 (0.59–0.90) b 2.50x10-3 d Endometrioid 
0.80 (0.71–0.90) b 1.93x10-4 d Other 
Kuchenbaecker 
et al. 2015 
rs56318008 European ancestry 
15437/30845 
0.15 1p36 WNT4 1.11 (1.06-1.15) a 8.00x10-7 
1.12 (1.06-1.17) 
a
 6.00x10
-6 Serous 
1.24 (1.10-1.39) 
a
 5.00x10
-4 Clear cell 
rs58722170 European ancestry 0.23 1p34.3 RSPO1 1.07 (1.03-1.11) a 2.00x10-4 1.12 (1.07-1.17) 
a
 4.00x10
-7 Serous 
rs17329882 European ancestry 0.24 4q26 SYNPO2 1.09 (1.06-1.13) a 3.00x10-7 
1.11 (1.07-1.16) 
a
 3.00x10
-7 Serous 
1.09 (1.01-1.18) 
a
 2.00x10
-2 Endometrioid 
rs116133110 European ancestry 0.31 6p22.1 GPX6 0.94 (0.91-0.97) a 9.00x10-5 0.91 (0.87-0.94) 
a
 3.00x10
-7 Serous 
rs6356 European ancestry 0.19 9q34.2 
Upstream of 
ABO 
1.12 (1.08-1.16) a 9.00x10-9 
1.13 (1.08-1.18) 
a
 2.00x10
-7 Serous 
1.12 (1.03-1.21) 
a
 7.00x10
-3 Endometrioid 
1.23 (1.10-1.38) 
a
 3.00x10
-4 Mucinous 
rs199661266 European ancestry 0.28 17q11.2 ATAD5 0.90 (0.87-0.93) a 1.00x10-9 
0.90 (0.87-0.94) 
a
 2.00x10
-7 Serous 
0.88 (0.82-0.95) 
a
 5.00x10
-4 Endometrioid 
0.88 (0.80-0.98) 
a
 2.00x10
-2 Clear cell 
BRCA1 
mutation 
carriers 
rs56318008 European ancestry 
Affected/unaffected 
(2462/12790) 
0.15 1p36 WNT4 1.15 (1.05-1.26) a, g 3.10×10−3    
rs58722170 European ancestry 0.23 1p34.3 RSPO1 1.14 (1.05-1.23) a, g 1.50x10-3    
rs17329882 European ancestry 0.24 4q26 SYNPO2 1.08 (1.00-1.17) a, g 4.20x10-2    
rs116133110 European ancestry 0.31 6p22.1 GPX6 0.92 (0.86-0.99) a, g 2.30x10-2    
rs6356 European ancestry 0.19 9q34.2 
Upstream of 
ABO 
1.11 (1.02-1.21) a, g 1.20x10-2    
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Supplementary Table 1 - Overview of OC susceptibility GWAS (cont.) 
The results shown in this table are the combined phases results of each study or the validation phases results (when conducted).a: per-allele; b: log-additive model; c: Ptrend; d: Pmeta; e:  MAF values for all 
populations obtained on “Ensembl” database; f: data obtained from “NCBI” database; g: HR values. The primary endpoint in this analysis was the age at ovarian cancer diagnosis. Mutation carriers were 
followed until the age of ovarian cancer diagnosis, or risk-reducing salpingo-oophorectomy or age at last observation. 
ǂ: replicated SNPs; #: validated SNPs 
Study Associated SNPs Population 
No. cases/controls 
(combined) 
MAF Locus Gene 
Overall risk Subtype-specific risk 
OR (95% CI) P-value OR (95% CI) P-value 
Histological 
subtype 
Kuchenbaecker 
et al. 2015 
(cont.) 
BRCA2 
mutation 
carriers 
rs58722170 European ancestry 631/7580 0.23 1p34.3 RSPO1 1.35 (1.17-1.57) a, g 5.20x10-5    
Keleman et al. 
2015 
rs752590 European ancestry 
1644 (mucinous subtype) 
/21693 
0.21 2q13 PAX8   1.34 (1.21-1.49) a 3.30x10−8 Mucinous 
rs711830 European ancestry 0.32 2q31.1 HOXD3   1.30 (1.20-1.40) a 7.50x10−12 Mucinous 
rs688187 European ancestry 0.32 19q13.2 IFNL3   0.67 (0.60-0.75) a 6.80x10−13 Mucinous 
Phelan et al. 
2017 
rs112071820 European ancestry 
25509/40941 
0.33 3q22.3 
Non-coding 
region 
  1.29 (1.20-1.37) a 1.50x10−13 Mucinous 
rs9870207 European ancestry 0.27 3q28 
Non-coding 
region 
  1.19 (1.12-1.27) a 4.50x10−8 Serous 
rs13113999 European ancestry 0.44 4q32.3 
Non-coding 
region 
  1.23 (1.14-1.32) a 4.70x10-8 Serous 
rs555025179 European ancestry 0.44 5q12.3 MAST4   1.18 (1.11-1.26) a 4.50x10-8 Endometrioid 
rs150293538 European ancestry 0.01 8q21.11 LINC01111   2.19 (1.65-2.90) a 2.00x10-9 Serous 
rs320203 European ancestry 0.12 9q31.1 LINC00587   1.29 (1.18-1.41) a 1.70x10-8 Mucinous 
rs7902587 European ancestry 0.12 10q24.33 
Non-coding 
region 
  1.29 (1.18-1.41) a 4.00x10-8 Serous 
rs8098244 European ancestry 0.31 18q11.2 LAMA3   1.19 (1.12-1.27) a 3.90x10-8 Serous 
rs6005807 European ancestry 0.09 22q12.1 MIR5739   1.17 (1.11-1.23) a 4.50x10-9 Serous 
BRCA1/2 
mutation + 
non-mutation 
carriers 
rs2165109 European ancestry 
BRCA1 mutation carriers 
(2933 
affected/16103unaffected) 
 
BRCA2 mutation carriers 
(954 affected/11458 
unaffected) 
0.25 2q13 LOC400997   1.09 (1.05-1.12) a 4.20x10-8 
Serous + 
BRCA1/2 
BRCA1/2 
mutation + 
non-mutation 
carriers 
rs9886651 European ancestry 0.46 8q24.21 MIR1204   1.08 (1.05-1.11) a 3.50x10-9 
Serous + 
BRCA1/2 
BRCA1/2 
mutation + 
non-mutation 
carriers 
rs7953249 European ancestry 0.42 12q24.31 
Non-coding 
region 
  1.08 (1.06-1.06) a 1.10x10-9 
Serous + 
BRCA1/2 
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Supplementary Table 2 - Overview of OC clinical outcome GWAS 
  
Study Associated SNPs Population 
No. 
cases/deaths 
(combined) 
MAF Locus Gene 
Overall risk Subtype-specific risk 
HR (95% CI) P-value HR (95% CI) P-value 
Histological 
subtype 
Bolton et al. 
2010 
rs8170 
ǂ
 All populations 8946/3354 0.11 
d 
19p13 
MERIT40 
OS 
1.11 (1.04-1.17) a 
5.20x10-4 b 1.28 (1.02–1.60) a 3.00x10-2 b Endometrioid 
rs2363956
 ǂ
 All populations 8900/3342 0.46 
d ANKLE1 
OS 
1.09 (1.04-1.14) a 
5.60x10-4 b 1.09 (1.03-1.16) a 5.20x10-3 b Serous 
Huang et al. 
2011 rs1649942 
ǂ
 
European ancestry 
Non-Hispanic white 
1703 cases 0.24 Chr10 NRG3 
PFS 
1.25 (1.03-1.52) a 
2.30x10-2 
   
PFS 
Optimally debulked patients 
1.43 (1.12-1.81) a 
4.00x10-3 
OS 
Optimally debulked patients 
1.48 (1.10-2.00) a 
9.00x10-3 
Johnatty et 
al. 2015 
“All 
chemotherapy” 
group 
rs6674079 
ǂ
 European ancestry 
4426 cases 
0.28 1q22 
RP11–
284F21.8 
OS 
1.15 (1.08-1.23) a 
7.10x10-6 
   
4095 cases 
PFS 
1.07 (1.01-1.13) a 
2.80x10-2 
rs7950311 
ǂ
 European ancestry 4426 cases 0.48 11p15.4 HBG2 
OS 
1.10 (1.04-1.17) a 
1.70x10-3    
rs4910232 
ǂ
 European ancestry 
4426 cases 
0.32 11p15.3 
RP11-
179A10.1 
OS 
1.12 (1.05-1.19) a 
9.40x10-4 
   
4095 cases 
PFS 
1.17 (1.10-1.24) a 
4.70x10-7 
rs2549714 
ǂ
 European ancestry 
4426 cases 
0.06 16q23 
RP11–
314O13.1 
OS 
1.20 (1.06-1.36) a 
3.40x10-3 
   
4095 cases 
PFS 
1.14 (1.01-1.28) a 
2.80x10-2 
rs3795247 
ǂ
 European ancestry 
4426 cases 
0.08 19p12 ZNF100 
OS 
1.16 (1.04-1.30) a 
8.80x10-3 
   
4095 cases 
PFS 
1.26 (1.14-1.40) a 
1.05x10-5 
“Standard 
chemotherapy” 
group 
rs7950311 
ǂ
 European ancestry 1799 cases 0.48 11p15.4 HBG2 
OS 
1.28 (1.16-1.42) a 
6.80x10-7    
rs4910232
 ǂ
 European ancestry 
1799 cases 
0.32 11p15.3 
RP11-
179A10.1 
OS 
1.20 (1.08-1.33) a 
5.30x10-4 
   
1598 cases 
PFS 
1.24 (1.12-1.56) a 
1.20x10-5 
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Study Associated SNPs 
Populatio
n 
No. 
cases/deaths 
(combined) 
MAF Locus Gene 
Overall risk Subtype-specific risk 
HR (95% CI) P-value HR (95% CI) P-value 
Histological 
subtype 
Johnatty et al. 
2015 (cont.) 
“Standard 
chemothera
py” group 
rs2549714 
ǂ
 
European 
ancestry 
1799 cases 
0.06 16q23 
RP11–
314O13.1 
OS 
1.53 (1.28-1.84) a 
5.00x10-6 
   
1598 cases 
PFS 
1.29 (1.08-1.55) a 
5.60x10-3 
rs3795247 
ǂ
 
European 
ancestry 
1799 cases 
0.08 19p12 ZNF100 
OS 
1.34 (1.13-1.60) a 
9.70x10-4 
   
1598 cases 
PFS 
1.39 (1.18-1.65) a 
9.20x10-5 
French et al. 
2016 
rs72700653 
ǂ
 
European 
ancestry 
1244 cases 
0.02 Chr9 
TTC39B 
  
PFS 
1.91 (1.36-2.69) a 
2.20x10-4 Serous 
rs7874043
 ǂ
 
European 
ancestry 
0.02 Chr9 
  
PFS 
1.90 (1.38-2.61) a 
7.30x10-5 Serous 
  
OS 
1.56 (1.09-2.23) a 
1.50x10-2 Serous 
Fridley et al. 
2016 
Paclitaxel 
MTT rs185229225 
European 
ancestry 
74 cases 
0.02 
Chr4: 
13609129 
BOD1L1 - e 2.20x10-7 c    
Caspase rs3842595 
European 
ancestry 
0.14 
Chr5:1217
78606 
MGC32805/ 
SNCAIP 
- e 2.60x10-7 c    
Carboplatin MTT rs150303591 
European 
ancestry 
0.29 
Chr4:7900
9309 
FRAS1 + f 5.90x10-7 c    
Combination 
MTT 
rs201023017 
European 
ancestry 
0.41 
Chr3:1431
03669 
SLC9A9 + f 6.00x10-7 c    
rs66696671 
European 
ancestry 
0.23 
Chr10:121
366953 
TIAL1 - e 7.30x10-7 c    
Caspase 
rs12025262 
European 
ancestry 
0.39 
Chr1:2473
56732 
ZNF731P - e 6.60x10-7 c    
rs10674174 
European 
ancestry 
0.42 
Chr13:618
92075 
PCDH20 - e 8.20x10-7 c    
Paclitaxel 
MTT 
rs35067965 
European 
ancestry 
0.33 d 
Chr18:455
396 
COLEC12 - e 
2.20x10-5    
Caspase 3.80x10-5    
Carboplatin 
MTT rs8091660 
European 
ancestry 
0.28 d 
Chr18:460
87936 
CTIF - e 
8.90x10-6    
Caspase rs113867814 
European 
ancestry 
Del d 
Chr18:462
59604 
1.20x10-5    
MTT rs2748151 
European 
ancestry 
0.28 d 
Chr20:601
33486 
CDH4 + f 
4.70x10-5    
Caspase rs113594423 
European 
ancestry 
0.10 d 
Chr20:603
79048 
2.40x10-5    
Carboplatin Caspase rs5830067 
European 
ancestry 
Del d 
Chr2:2853
7890 
BRE 
+ f 1.70x10-5    
Combination Caspase rs7572644 
European 
ancestry 
0.28 d 
Chr2:2832
0033 
- e 5.80x10-6    
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The results shown in this table are the combined phases results of each study or the validation phases results (when conducted). 
a: per-allele; b: Ptrend; c: Pmeta; d:  MAF values obtained on “Ensembl” database; e: (-), carriers of the minor/variant allele are, on average more sensitive to chemotherapeutic agents (lower IC50 or EC50); f: 
(+), carriers of the minor/variant allele are, on average more resistant to chemotherapeutic agents (higher IC50 or EC50). 
ǂ: replicated SNPs; #: validated SNPs 
 
 
Study Associated SNPs Population 
No. 
cases/deaths 
(combined) 
MAF Locus Gene 
Overall risk Subtype-specific risk 
HR (95% CI) P-value HR (95% CI) 
P-
value 
Histological 
subtype 
Fridley et al. 
2016 (cont.) 
Paclitaxel Caspase rs75314082 European ancestry 
74 cases 
0.09 d Chr2:55087315 
EML6 
- e 7.90x10-5    
Combination MTT rs17046344 European ancestry 0.17 d Chr2:55023600 + f 4.90x10-5    
Paclitaxel Caspase rs72817940 European ancestry 0.09 d Chr2:58998563 
LINC01122 
+ f 6.40x10-5    
Carboplatin Caspase rs4233974 European ancestry 0.38 d Chr2:59295043 - e 2.60x10-5    
Carboplatin MTT rs17261321 European ancestry 0.39 d Chr2:80197843 
CTNNA2 
+ f 3.60x10-5    
Combination MTT rs6719499 European ancestry 0.31 d Chr2:80193386 - e 6.00x10-5    
Paclitaxel MTT rs1525599 European ancestry 0.12 d Chr2:141778702 
LRP1B 
+ f 8.60x10-5    
Combination Caspase rs13020675 European ancestry 0.26 d Chr2:142212928 - e 6.20x10-5    
Paclitaxel Caspase rs201083182 European ancestry Del d Chr6:65736914 
EYS 
- e 2.30x10-6    
Combination Caspase rs2064701 European ancestry 0.17 d Chr6:65676556 + f 3.60x10-5    
Paclitaxel Caspase rs550987 European ancestry 0.22 d Chr6:124905510 
NKAIN2 
- e 4.10x10-5    
Combination Caspase rs670616 European ancestry 0.28 d Chr6:124885773 + f 7.80x10-5    
Carboplatin Caspase rs10230114 European ancestry 0.29 d Chr7:47705506 
C7orf65 
+ f 2.40x10-5    
Combination Caspase rs11771997 European ancestry 0.43 d Chr7:47712495 + f 2.40x10-5    
Paclitaxel Caspase rs12572446 European ancestry 0.49 d Chr10: 47665906 
ANTXRL 
+ f 4.30x10-5    
Combination Caspase rs10906942 European ancestry 0.50 d Chr10: 47670851 + f 4.90x10-5    
Carboplatin Caspase rs10999018 European ancestry 0.06 d Chr10: 71654602 
COL13A1 
+ f 2.40x10-5    
Combination Caspase rs77535242 European ancestry 0.06 d Chr10: 71652985 + f 3.50x10-5    
Paclitaxel Caspase rs77438645 European ancestry 0.07 d Chr12:130304313 
TMEM132D 
- e     
Carboplatin Caspase rs1451904 European ancestry 0.39 d Chr12:130166947 + f 6.50x10-5    
Carboplatin Caspase rs690089 European ancestry 0.40 d Chr18: 8845223 
MTCL1 
- e 7.80x10-5    
Combination Caspase rs35765215 European ancestry 0.16 d Chr18:8839469 - e 6.00x10-5    
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Appendix 3 
Supplementary Table 3 - Overview of molecular pathways which susceptibility associated SNPs are known to be involved 
  
Study SNP Gene Molecular pathway a Functional consequence 
Song et al. 2009 rs3814113 
~44 kb upstream of 
BNC2 gene 
 
Deletion of 5 kb surrounding rs3814113 decreased BNC2 
expression levels [204] 
Bolton et al. 2010 
rs8170 MERIT40 
DNA double strand break response; 
Cell cycle checkpoints 
 
rs2363956 ANKLE1 Human lymphocyte development [205]  
Goode et al. 2010 
rs2665390 TIPARP Aryl hydrocarbon receptor signaling [206]  
rs9303542 SKAP1 
B-cell receptor signaling pathway; 
RAS signaling pathway 
 
Couch et al. 2013 
rs17631303 PLEKHM1 
Osteoclast function regulation [207]; 
Bone resorption [207]; 
Endocytic and autophagy pathways [207] 
 
rs183211 NSF 
Delta508-CFTR (cystic fibrosis transmembrane conductance 
regulator) traffic / Sorting endosome formation in CF (cystic fibrosis); 
Trafficking of AMPA receptors; 
Vasopressin-regulated water reabsorption 
 
Pharoah et al. 
2013 
rs11782652 CHMP4C 
HIV life cycle; 
MTOR signaling; 
Endocytosis 
Association between rs11782652 and CHMP4C 
overexpression in primary EOC tissues and LCLs [139].   
rs1243180 MLLT10 Leukemogenesis [208] 
Association between rs1243180 and C10orf114 and 
SKIDA1 expression in primary EOC tissues  [139]. 
rs757210 HNF1B 
Regulation of β-cell development; 
Type II Diabetes Mellitus; 
Hepatic ABC transporters 
Association between the minor allele of rs757210 and 
overexpression of HNF1B in serous EOC tissues [139].  
Earp et al. 2014 
rs17106154 
~150 kb in LD region of 
ZFP36L1 (BRF1) gene 
Validated targets of C-MYC transcriptional repression; 
PI3K / Akt signaling; 
Translational control 
 
rs2190503 
Identify a locus 
upstream/intronic to 
GRB10 gene 
IGF1 pathway; 
Signaling events regulated by Ret tyrosine kinase; 
Insulin pathway 
 
rs6593140  
rs2329554  
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Supplementary Table 3 - Overview of molecular pathways which susceptibility associated SNPs are known to be involved 
a: data obtained from “GeneAnalytics” database (exceptions are referenced) 
 
Study SNP Gene Molecular pathway a Functional consequence 
Earp et al. 2014 
(cont.) 
rs9609538 
~5 bp downstream of 
BPIL2 gene and ~500 
bp upstream of 
C22orf28 
 
The minor allele of this SNP is predicted to alter 
transcription factor binding site activity and miRNA 
binding site activity [141]. 
Chen et al. 2014 
rs1413299 COL15A1 
Protein digestion and absorption; 
Collagen biosynthesis and modifying enzymes; 
Degradation of the extracellular matrix 
 
rs11175194 SRGAP1 
Signaling by Robo receptor; 
Regulation of RhoA activity; 
Signaling by Slit 
 
Kuchenbaecker et al. 
2015 
rs56318008 WNT4 
Negative regulation of TCF-dependent signaling by WNT ligand 
antagonists; 
WNT ligand biogenesis and trafficking; 
Mesenchymal Stem Cell differentiation pathways and lineage-specific 
markers 
No effect on WNT4 transcription in OC cells [143] 
rs58722170 RSPO1 
Regulation of FZD by ubiquination; 
WNT signaling; 
Signaling by GPCR 
 
rs17329882 SYNPO2 Actin binding protein [209]  
rs116133110 GPX6 
Folate metabolism; 
Detoxification of Reactive Oxygen Species; 
Selenium metabolism and selenoproteins 
 
rs199661266 ATAD5 DNA damage response [143]  
Keleman et al 
rs752590 PAX8 
ID signaling pathway; 
Thyroid cancer; 
TSH signaling pathway 
 
rs711830 HOXD3 
Activation of HOX genes during differentiation; 
Developmental Biology 
 
rs688187 IFNL3 
Peginterferon alpha-2a/Peginterferon alpha-2b Pathway; 
all-trans-Retinoic Acid Mediated Apoptosis; 
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways 
 
Phelan et al. 2017 
rs555025179 MAST4 Microtubule scaffolding [210]  
rs8098244 LAMA3 
Syndecan-family-mediated signaling events; 
Validated transcriptional targets of AP1 family members Fra1 and Fra2; 
Alpha 6 Beta 4 signaling pathway 
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Appendix 4 
Supplementary Table 4 - Overview of molecular pathways which clinical outcome associated SNPs are known to be involved 
 
 
 
 
Study SNP Gene Molecular pathway Functional consequence 
Bolton et al. 2010 
rs8170 MERIT40 
DNA double strand break response; 
Cell cycle checkpoints 
 
rs2363956 ANKLE1 Human lymphocyte development [205]  
Huang et al. 2011 rs1649942 NRG3 
ErbB4 signaling events; 
Signaling by ErbB2; 
Agrin Interactions at Neuromuscular Junction 
This SNP is associated with baseline 
expression of 18 genes [136] 
Johnatty et al. 2015 
rs7950311 HBG2 
Factors involved in megakaryocyte development and platelet production; 
IL-2 pathway; 
p70S6K signaling 
 
rs3795247 ZNF100 Gene expression  
French et al. 2016 
rs72700653 
TTC39B 
Mediation of the 
association of HDL-regulating proteins [211] 
The minor alleles of these SNPs 
enhance expression of the non-
canonical TTC39B promoter [144] rs7874043 
Fridley et al. 2016 
rs185229225 BOD1L1 Replication fork protection factor [151]  
rs3842595 SNCAIP/MGC32805 
Putative ubiquitin pathway; 
Parkinson’s disease pathway; 
Parkin-Ubiquitin proteasomal system pathway 
 
rs150303591 FRAS1 
Phospholipase-C pathway; 
Integrin pathway; 
ERK signaling 
 
rs201023017 SLC9A9 
Sweet taste signaling; 
Transport of glucose and other sugars, bile salts and organic acids, metal 
ions and amine compounds 
 
rs66696671 TIAL1 
Formation of the HIV-1 Early Elongation Complex; 
Apoptosis and autophagy; 
Translational control 
 
rs10674174 PCDH20 WNT signaling (Antagonist) [212]  
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Supplementary Table 4 - Overview of molecular pathways which clinical outcome associated SNPs are known to be involved 
 
a: data obtained from “GeneAnalytics” database (exceptions are referenced) 
 
Study SNP Gene Molecular pathway Functional consequence 
Fridley et al. 2016 
(cont.) 
rs35067965 COLEC12 
Binding and uptake of ligands by Scavenger receptors; 
Phagosome; 
Vesicle-mediated transport 
 
rs8091660 
CTIF Translation initiation [213] 
 
rs113867814  
rs2748151 
CDH4 
CDO in myogenesis; 
Natural Killer cell receptors; 
S-1P stimulated signaling 
 
rs113594423  
rs5830067 
BRE 
Apoptosis and survival-caspase cascade; 
DNA double strand break response [145]; 
TWEAK pathway 
 
rs7572644  
rs75314082 
EML6 Microtubules dynamics regulation [145] 
 
rs17046344  
rs1525599 
LRP1B Metabolic health programming [214]  
rs13020675 
rs17261321 
CTNNA2 
CDO in myogenesis; 
Adhesion [145]; 
Adherens junction 
 
rs6719499  
rs10999018 
COL13A1 
Articular cartilage extracellular matrix pathway; 
T Cell co-signaling pathway: ligand-receptor interactions; 
Natural Killer cell receptors 
 
rs77535242  
rs690089 
MTCL1 Microtubule dynamics regulation [215] 
 
rs35765215  
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Appendix 5 
 A paper entitled Rethinking ovarian cancer genomics: where GWAS stand? has 
been submitted and accepted for publication in the scientific journal Pharmacogenomics. 
 
 
